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The interplay between cancer cells and adjacent stroma is fundamental for the 
development and progression of tumours. In fact, this crosstalk sustains carcinogenesis 
and promotes the acquisition of additional malignant features. In prostate cancer (PCa), 
cancer-associated fibroblasts (CAFs) have been shown to fuel tumour development and 
metastasis by mutually interacting with tumour cells. In this regard, defining stromal 
gene signatures relevant for cancer progression could be a successful strategy to 
identify novel therapeutic targets and prognostic biomarkers for PCa. Recently, we 
have performed a gene expression profiling analysis comparing CAFs and fibroblasts 
stimulated with IL-6 or TGF-β, to examine the molecular signatures involved in 
fibroblast activation. The gene set enriched analysis revealed that CAFs are 
characterized by positive enrichment of genes coding for calcium, sodium, and 
potassium cation channels and genes related to extracellular matrix (ECM)-
remodelling. This evidence suggests a crucial role of characteristic stromal-related 
pathways in fibroblast conversion to a phenotype able to sustain PCa progression. In 
addition, the definition of reactive stroma players that are crucial for cancer progression 
could be a strategy to identify novel therapeutic targets and biomarkers for the early 
detection of aggressive PCa.  
To better understand the involvement of cation channels in CAFs activation and 
potentially revert such activated phenotype, in this work we treated CAFs with specific 
cation channel inhibitors, such as antiarrhythmics. Interestingly, we found that 
antiarrhythmics are able to interfere with crucial features of prostate CAFs, as indicated 
by the modulation of specific activation markers and reduction of contraction and 




are able to impair CAF-induced proliferative spur and EMT in PCa cells, and 
ultimately induce tumour growth delay in vivo.  
Given the ability of a reactive stroma to support cancer progression, the prognostic 
relevance of selected genes found up-regulated in activated fibroblasts was tested in 
relation to clinical-pathological characteristics and patient outcome.  
Among crucial factors found up-regulated in prostate CAFs compared to normal 
fibroblasts we identified a set o ECM-remodelling protein, including periostin. 
Interestingly, the immunostaining analysis we performed in a series of prostatectomies 
from PCa patients confirmed that periostin is mainly expressed in the stroma 
components surrounding tumour foci, and that its staining correlates with tumour grade 
and cribriform gland morphology, which is indicative of adverse outcome. Most 
importantly, high levels of stromal periostin expression were associated with a 
significantly increased probability to experience biochemical recurrence after 
prostatectomy. In light of the positive correlation observed between periostin stromal 
staining and aggressive disease, we also investigated the prognostic potential of 
circulating periostin in patients with potentially indolent tumours followed in the 
context of an active surveillance protocol. However, results from the study indicated 
that baseline plasma levels of periostin displayed a moderate capability to identify 
patients with aggressive disease.  
Overall these studies may open new opportunities for the translation of drugs 
already used in different fields into the targeting of tumour-associated fibroblasts with 
the aim to interrupt their tumour-supportive spur. Finally, the characterisation of 
relevant stromal gene signatures may improve diagnostic tools for an early 
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1.1. Prostate Cancer 
1.1.1. Epidemiology 
According to global cancer statistics 2018, prostate cancer (PCa) represents the 
second worldwide diagnosed solid tumour, and the fifth cause of cancer death in 





Figure 1.1. Pie charts present the distribution of cases and deaths for the 
10 Most common cancers in 2018 for males. The area of the pie chart 
reflects the proportion of the total number of cases or deaths; nonmelanoma 









The development of advanced diagnostic procedures and the increased aging of 
population, has led to a higher incidence of PCa diagnosis in Western countries. 
Although the risk factors related to PCa development are not fully understood, 
increasing evidence strongly links PCa and patient age 
2
. The age–adjusted PCa 
incidence is 0.0005% in men younger than 39 years, and increases to 13.7% for 
those aged 60-79 years 
3
. Moreover, PCa seems to be associated with family 
history. In fact, the link between hereditary factors and PCa was described in a 
case-control study, which highlighted that the risk of developing PCa was twice 
higher in men who had an affected brother or father with respect to those not 
having any tumour case in their family 
2
.  
In the era of genomics, the presence of mutations in specific genes, such as BRCA1 
and BRCA2, has been implicated in increasing the risk of PCa 
4
. In this regard, the 
identification of men with genetic predisposition of prostate cancer (IMPACT) 
study showed that BRCA2 mutation is associated with an increased frequency of 
intermediate or high-risk PCa 
4
.  
Finally, increasing evidence has established a correlation between PCa 
development and recurrent prostate gland inflammations. At the present, the role of 
chronic inflammation in PCa is not clear yet. However, several studies have 
reported that viruses, bacteria or toxic agents can cause prostatitis or severe 








In the 1979, the discovery of prostate-specific antigen (PSA) had completely 
changed PCa diagnosis and replaced the previously used prostatic acid phosphatase 
test 
6
. The PSA is a glycoprotein produced by the normal as well as malignant cells 
of the prostate gland. In the early 1990s, the FDA established a novel clinical 
practice which combines PSA test and the digital rectal exam for asymptomatic 
PCa diagnosis 
7
. Specifically, the PSA test is based on the detection of PSA levels 
in the blood. PSA levels ≤ 4.0 ng/ml are considered normal, higher than 4.0 are 
supposedly indicative of PCa 
8
. However, also benign prostate hyperplasia, 
prostatitis and urinary infections are disease conditions associated with high serum 
PSA levels. In this context, despite the widespread use, the PSA test displays a low 
specificity for clinically relevant disease, in fact a great amount of patients carrying 
high-grade tumours display low levels of PSA in the blood 
9,10
. On this basis, PSA 
screening has fallen under controversy, especially regarding the limited specificity 
of this test in properly detecting PCa. However, approximately 25% of the men that 
exhibit elevated PSA levels in the blood will receive a diagnosis of PCa 
11
.  
PCa diagnosis is based on the examination of histopathological specimens obtained 
by trans-rectal or trans-perineal ultrasound guided core biopsies. Recently, the 
fusion of the magnetic resonance imaging with real time ultrasonography, thus 




PCa is classified according to the Gleason Pattern Score (GS). Donald Gleason 






system is based on histological appearance of tumour cells, and it consists of the 
description of the glandular differentiation extent and growth within the prostate 
stroma. In details, the GS is the sum of two scores, ranging from 1 (well- 
differentiated) to 5 (undifferentiated), representative of the most dominant and the 





Figure 1.2. Schematic representation of the grading system developed by 
Gleason. (Adapted from N. J. Sathianathen Nature Reviews Urology 
14
) 
In the 2005, the International Society of Urological Pathology (ISUP) modified the 
original GS during a consensus conference 
15
. Substantial modifications were 
Gleason’s pattern score
Small uniform glands




Irregular masses of 
neoplastic cells with few glands
Only occasional glands formation, 











recommended, including the morphologic criteria to interpret cribriform pattern 4 
with respect to cribriform pattern 3. In the 2014, the original scheme proposed by 
Gleason has been dramatically modified, resulting in the total elimination of 1 and 
2 score from diagnosis. According to the new grading system, a grade shift was 
introduced. Specifically, certain GS 6 tumours are now considered 7, thus 
improving the concordance between needle biopsy and prostatectomy pathology. 
Concomitantly, a subgroup of GS 6 tumours was reported to display a better 
prognosis than the historic one 
16
. Subsequently, Epstein and collaborators 
introduced a Modified Gleason Scoring Classification in the 2016. This last change 
includes five grading groups: grade group 1 (GS ≤ 6), grade group 2 (GS 3+4 = 7), 
grade group 3 (GS 4+3 = 7), grade group 4 (GS 4+4 = 8), and grade group 5 (GS 9–
10) (Table 1.1). Mainly, this innovative grading system established the 
identification of two different subgroups associated with GS 7 tumours. 
Specifically, therapeutic decision-making based on the previous single GS 7 
tumours failed to recognize that 3+4=7 and 4+3=7 are very different from a 
prognostic point of view. The establishment of the Epstein grading system, 













Finally, the PCa staging is still based on the tumour-node-metastasis (TNM) 
system. This classification is used to stage different types of cancer an it is based on 
the size and anatomical extent of the tumour (T), the number of lymph nodes that 





1.2. Prostate Cancer Management 
As various malignancies, the treatment of PCa depends of the staging, defined by 
the anatomical extension and aggressiveness of the disease. Since PCa is a disease 
mostly frequent in elderly men, the life expectancy of the patient and the presence 
of comorbidities may complicate the therapeutic decision-making process 
18
. 
Moreover, the quality of life, together with the oncological outcome, is also 
relevant in PCa management.  
In this setting, the PCa management includes conservative approaches, such as 
active surveillance or watchful waiting, and curative treatments, such as radical 
prostatectomy or radiotherapy, hormone therapy and chemotherapy.  
However, the survival benefits of these treatments and their efficacy remain 
controversial.  
 
1.2.1. Clinically insignificant PCa  
Active surveillance (AS) and watchful waiting are conservative protocols for 
clinically insignificant PCa. Truly indolent PCa display a very low metastatic 
potential, which allows the disease monitoring in order to avoid or temporally delay 
treatment-induced adverse effects in patients 
19
. The main purpose of AS and 
watchful waiting is to prevent over-treatment and potentially enhance quality of life 
in patients who received the diagnosis of indolent PCa. Watchful waiting strategy is 
based on the monitoring of symptoms of local or distant PCa progression and is 






AS was adapted from watchful waiting, and it is an active and extensive way for 
monitoring localised and early stage PCa, characterised by a very slow potential 
progression. This monitoring approach is exclusively proposed to patients with a 
low risk and clinically insignificant disease. Robust evidence indicated that most 
patients enrolled in AS likely never develop PCa-related symptoms 
19
. However, at 
the first sign of a major risk, radical treatments will be addressed in order to cure 
the tumour, while still maintaining high chances of healing.  
The crucial event in AS strategy is the correct and univocal identification of 
patients truly suitable for the protocol, who are those that harbour an “insignificant 
tumour”. This subgroup of men who received a diagnosis of insignificant PCa 
manly carry a “pseudo-disease” that could be part of the ageing process and does 
not pose a significant threat to their lives 
20
. In accordance with the Epstein and 
D’Amico risk-classification, “insignificant tumours” include very-low and low-risk 
PCa, which are characterised by stage T2a or lower, Gleason 6 tumour or less on 
biopsy cores, no more than two positive cores, no involvement of more than 50% of 
a positive core, PSA levels < 10 ng/ml and PSA density less than 0.15 ng/ml/ml 







Table 1.5. Risk classification of very low, low risk PCa, 
according to D’Amico 
21





During AS, the evolution of the tumour is observed, and the schedule of monitoring 
includes: the dosage of PSA levels in the blood every 3 months (possibly always 
performed by the same laboratory); an urological visit with rectal exploration to 
evaluate the prostate (shape, size, texture) at least every 6 months and a prostate 
biopsy after 1 year of inclusion (and then after 4 and 7 years). In case of positivity 
to the examinations patients are immediately redirected to radical treatment.  
Ideally, the AS programme should monitor patients characterised by a very slow 
tumour progression. However, multiple studies reported that, at the first re-biopsy, 
about 25% of enrolled patients harbour a clinical relevant PCa and drop out from 
the protocol, indicating that this minority might have been incorrectly classified as 
carriers of <insignificant disease 
23
. Therefore, the critical aspect for successful AS 
is the best possible selection of patients with truly “insignificant tumours”. In this 




magnetic resonance imaging into AS selection criteria might improve the detection 




Overall, the AS patient treatment rates at 10 and 15 years is about 36% and 45%, 
respectively. Moreover, about the 90% of patients enrolled in AS can be expected 
to have organ-confined disease, without compromising the oncological outcome. In 
light of this evidence, AS might be considerate the ideal options for men with very-




1.2.2. Clinically relevant PCa  
Radical treatments, which are surgery and radiotherapy, represent the main 
therapeutic options for clinically localized PCa, providing the highest efficacy in 
terms of healing from the disease. Surgery consists of the entire removal of the 
prostate, seminal vesicles and pelvic lymph nodes. The main criticisms related to 
radical prostatectomy procedures are urinary incontinence and rectal dysfunction 
events. As for urinary incontinence, it is a disorder that manifests itself in the vast 
majority of patients immediately after surgery, but often regresses within three 
months. Current understanding of prostate anatomy and retro prostatic 
neurovascular bundles has led to develop a conservative nerve-sparing 
prostatectomy. This surgical approach represents the modern standard radical 
prostatectomy procedure able to significant reduce the occurrence of postoperative 
erectile dysfunction. At the present, the “open-air” radical prostatectomy has been 
almost completely replaced by a mini invasive approach that allows operating by 5 




robot-assisted laparoscopy and 3D stereoscopic visualization has led to develop a 
mini-invasive radical prostatectomy surgery, which it is comparable with open 
procedure in terms of oncological and functional outcomes. 
Similar to radical prostatectomy, radiotherapy is a first line treatment for clinically 
localized PCa. The therapeutic outcomes provided by radiotherapy are comparable 
with those of prostatectomy, and therefore the choice between prostatectomy and 
radiotherapy is concerted between the patient and the clinicians. At present, the 
main types of radiation techniques used for PCa treatment are external beam 
radiotherapy and brachytherapy. The main goal of external beam radiotherapy is to 
reach the maximum radiation dose at the target organ with the least adjacent tissue 
damage. Differently from external radiotherapy, brachytherapy is a type of 
irradiation modality where tiny radioactive seeds are placed into the prostate. This 
approach improves the efficacy of the treatment since the radiation is directly 
delivered within the prostate. Recently, the advent of 3D conformal radiotherapy 
and intensity-modulated radiotherapy have further improved the delivery of the 
treatment and substantially reduced side effects, which are related to the tissue 
toxicity induced by radiation on prostate surrounding tissues and local organs. 
Finally, it is also worth mentioning of the role of adjuvant radiotherapy in patients 
with adverse pathological features after prostatectomy. When the tumour extends 
beyond the prostatic capsule thus increasing the risk of local relapse, radiotherapy 
is delivered immediately post-operation. It is a treatment option highly 
recommended for patients with an early-stage localised disease, being a minimally 
invasive treatment that is performed in day-surgery, characterized by a low rate of 






The first line of treatment against advanced prostate cancer is represented by 
androgen deprivation therapy (ADT). The basis for ADT in PCa has been 
established by the Noble prize-winning finding that highlighted the relevance of 
androgen hormones in PCa cell growth 
26,27
. Androgens can be surgically depleted 
using orchiectomy. However, this surgical castration procedure has been largely 
replaced by pharmacological suppression. Pharmacological methods are based on 
the use of luteinizing hormone-realising hormone (LH-RH) or goserelin acetate 
(GnRH) agonists and androgen antagonists. The LH-RH or GnRH agonist acts by 
blocking the luteinizing hormone (LH) production, thus resulting in the suppression 
of the androgen hormone production by the testicles. As for androgen antagonists, 
these drugs are used to compete with androgen hormones for binding to its receptor 
on cell surfaces and block prostate cell stimulation induced by the hormones. 
Differently from LH-RH agonists, androgen antagonists cause less erectile 
dysfunction but more side effects on breast tissue. Ciproterone acetate, 
cicalutamide, futamide, enzalutamide are common androgen antagonists used in the 
clinical practice. Among the androgen antagonists, abiraterone acetate is an oral 
anti-androgen able to target the biosynthesis of androgen hormones, manly used in 
the management of castration-resistant PCa and recently approved in the pre-
chemotherapy setting 
28
. At present, hormone therapy may be used before, during 
or after surgery or radiotherapy. However, the timing and the schedule of ADT 
administration in PCa patients have several controversial aspects. In this regard, 
recent data demonstrate that immediate administration of ADT in men with 
biochemical relapse following radical treatments improves overall survival of 
patients and reduces the risk of recurrence. Moreover, data regarding the potential 




administration of hormone therapy substantially reduces the adverse effects induced 
by ADT.  
In order to enhance the quality of life and substantially improve overall survival for 
men with castration resistant PCa (CRPC), chemotherapy is used. Taxane-based 
chemotherapy in association with prednisone represents a valid treatment used in 
this PCa patient setting. The first agent that showed an improvement of both quality 
of life and progression free-survival in CRPC patients was docetaxel 
29
. 
Subsequently, also cabazitaxel has been demonstrated to improve survival in CRPC 
patients 
30
. Currently, data derived form several clinical trials indicated that the 
standard therapy for CRPC is represented by the combination of docetaxel and 
ADT (168-172).  
In advanced PCa, bone metastasis occurrence is the predominant event. In this 
setting, differently from palliative radiotherapy, radium-223 α-particle emitter is the 
only approved therapy used to target bone metastasis in PCa patients (187). 
Concerning the immunotherapy approaches, the Sipuleucel-T vaccine has been 
recently approved in the USA. The use of this autologous active cellular immune 







1.3. Diagnostic and prognostic biomarkers to guide the early detection 
of PCa  
1.3.1. Diagnostic Biomarkers 
At present, PSA is the only approved biomarker able to aid the early detection of 
PCa, indicate disease recurrence after radical treatments and determine the efficacy 
of drug therapies. However, the advent of PSA screening has led to PCa 
overdiagnosis and overtreatment, pointing out the low specificity of this test for 
clinically relevant PCa 
32
. The moderate capability of PSA screening to identify 
indolent from aggressive tumours was confirmed by multiple studies, which 
highlighted that PSA-based screening provide only 25% of PCa specific-mortality 
reduction in face of elevated cost of overdiagnosis 
33,34
.  
In order to aid clinicians in the early detection and categorisation of PCa, PSA-
related markers were combined in promising diagnostic and prognostic models. An 
improvement of specificity in PCa diagnosis has been observed by using free-PSA 
(fPSA) ratio. Although the total PSA (tPSA) is mainly complexed with serum 
proteins, a correlation between fPSA fraction and PCa has been observed. 
Specifically, a lower % fPSA was associated with the presence PCa in those 
patients who displayed modest levels of tPSA (4-10 ng/ml) with respect to PCa-free 
men 
35,36
. In addition, Prostate Health Index (PHI) was developed by combining 
tPSA, fPSA and (-2)proPSA, which is a fPSA isoform showing an elevated 
specificity for PCa 
37
. Multicentre studies indicated that the specificity of PHI 
model for the detection of clinically relevant PCa was about 38% 
38
. Hence, the PHI 
model displays a higher specificity for PCa than tPSA, and a significant association 




biochemical recurrence following radical prostatectomy, thus indicating a possible 
use of PHI as prognostic biomarker 
39
. In light of these findings, the % fPSA and 
the PHI model were approved for men with 4-10 ng/ml tPSA levels before initial or 
repeat biopsy.  
Interestingly, the innovative Progensa is a test to measure the urine levels of 
prostate cancer antigen 3 (PCA3) non-long-coding RNA, which is unexpressed in 
normal and hyperplast prostate 
40
. The function of PCA3 is currently unknown, 
however its levels in the first-void or post digital-rectal examination urine were able 
to predict PCa with a specificity of the 79% in a cohort of men with elevated PSA 
levels and prior negative biopsy 
41
. Several studies highlighted the greater accuracy 
of PCA3 for PCa detection with respect to tPSA, especially when it is used as a 
score. However, further investigations indicated that PCA3 score is not associated 
with progression in AS or after radical treatments. Moreover, discrepancies 
emerged regarding the establishment a univocal cut-off value of PCA3 score for 
PCa detection 
42,43
. To date, PCA3 test with a cut-off score of 25 was approved by 
FDA for men age > 50 with a previous negative biopsy.  
The limitations of the current clinical examination tests and the advances in 
understanding the molecular biology of PCa have led to the development of more 
sensitive biomarkers. In the genomic era, the mutational landscape of organ-
confined PCa has been investigated, highlighting significant genomic alterations 
that could potentially guide the early detection of PCa. For instance, recurrent 
somatic TMPRSS2-ERG gene fusion was described in over 50% of all PCa and was 
associated with PCa-specific mortality 
44
 . Moreover TMPRSS2-ERG gene product 




PCa but at the cost of a low sensitivity (about to 37%) 
45
. In light of this, the 
molecular assay “Mi Prostate score” based on combining TMPRSS2-ERG RNA 
and PCA3 detection in the urine samples and serum PSA levels has displayed a 
95% of sensitivity and 38% of specificity for aggressive PCa 
46
.  
Other genomic alterations were commonly observed in early-stage PCa, including 
SPOP, TP53, FOXA1 and IDH1 mutations, and also PTEN loss, MYC amplification 
and PI3K signalling activation 
47,48
. These findings substantially improved the 
knowledge of PCa carcinogenesis, however an association between PCa different 
molecular subtypes and progression or lethality has not been clarified yet. In this 
regard, further efforts are needed to develop an accurate molecular screening for the 
early detection of PCa.  
Since DNA hyper-methylation occurs very frequently in many cancers, its potential 
as a biomarker for early detection of PCa was investigated. In this regard, the 
ConfirmMDx assay has been developed to assess the methylation state of GSTP1, 
APC and RASSF1, which were previously found to be associated with PCa. 
Notably, the ConfirmMDx epigenetic assay could be potentially used for the 
identification of a “cancerization field” effect in negative core biopsies, thus 
indicating the presence of occult PCa or predicating its development 
49
. However, 
the diagnostic accuracy for clinically relevant PCa was not confirmed yet (Table 
1.3.). 
  
1.3.2. Prognostic biomarkers 
The Gleason score is the most used clinical prognostic marker for PCa, displaying a 




grading modifications introduced by Epstein have further improved its prognostic 
potential to predict biochemical recurrence after radical treatments when tested in a 
cohort of 20,000 patients 
22
. Moreover, D’Amico risk stratification model, which 
combines clinical factors, such as Gleason score, stage and PSA, is actually the 
most robust and widely-used tool to define disease recurrence and guide decision-
making regarding additional or adjuvant therapy upon radical treatments 
21
. 
However, limited tools are available for reducing the risk of under-sampling during 
prostate biopsy and clearly predict unfavourable disease. In this regard, several 
promising potential tools are currently in different stages of development or under 
investigation. Among these, the OncotypeDX™ score is a genomic assay based on 
the detection of 17 genes related to androgen signalling, stroma response, cell 
organization and proliferation. This tool has demonstrated a good performance for 
predicting aggressive disease in very-low, low and intermediate PCa settings. 
Notably, this assay could be potentially used as a valid tool in the post-biopsy 
setting for reducing the risk of PCa under-sampling and guide decision-making in 
AS protocol 
50
. In addition, the RNA-based Prolaris™ molecular assay has shown a 
good prognostic potential in terms of biochemical recurrence after radical 
treatments. This assay has been retrospectively tested in a large cohort of paraffin-
embedded specimens and it was able to predict biochemical relapse, by providing a 
mathematical score derived from the combination of 31-gene expression levels. 
Another RNA-based genomic assay is the Decipher™, a 22-gene assay that was 
able to predict development or early metastasis after treatment 
51
. Currently, 
Decipher™ and Prolaris™ assays are under prospective validation. Finally, the 
Promark™ in-situ proteomic multi-marker assay has been tested on Gleason 3+3 




despite biopsy under-sampling 
52
. This proteomic test is mentioned in the NCCP 
PCa guidelines as a promising tool for risk assessment in the post-biopsy setting for 
who men that are considering AS protocol (Table 1.3.).  
 
 




Biomarker  Type  Specimen type  Application 
PSA Protein Blood Diagnostic 









ConfirmMDX Epigenetic DNA  Prostate tissue Diagnostic 
OncotypeDX™  DNA  Prostate tissue Prognostic 
Prolaris™  RNA  Prostate tissue Prognostic 
Decipher™  RNA  Prostate tissue Prognostic 




1.4.  Tumour microenvironment  
 
1.4.1. Cancer-associated fibroblasts in cancer progression 
Tumour growth into a full malignancy is not just determined by cancer cells 
themselves, but also by several non-cancer cells within the tumour 
microenvironment. Immune cells, endothelial cells, structural components and 
cancer-associated fibroblasts (CAFs) are actively involved in cancer development.  
Among the key components of the tumour microenvironment, it is becoming clear 
that CAFs are prominent modifiers of several carcinogenesis steps, including 
cancer initiation, development and progression 
53
. In fact, CAFs orchestrate the 
synthesis and modulation of extracellular matrix (ECM) and the release of pro-
tumourigenic factors. Moreover, CAFs can induce angiogenesis, create an 
immunosuppressive environment and regulate cancer therapy responses.  
In the last decade, a great expansion into CAF-related research has enhanced our 
knowledge of this subpopulation and brought out novel potential therapeutic 
strategies against cancer aimed at targeting CAFs. However, their origins, features 
and functions within the tumour microenvironment are still not fully established. 
Emerging evidence indicates that CAFs are involved in complex interactions with 
cancer cells, having both tumour-promoting and suppressing functions 
54–56
.  
In normal tissues, fibroblasts are elongated cells embedded in the connective tissue, 
and negative for epithelial, endothelial and leukocyte markers. They are involved in 
ECM deposition, epithelial cell differentiation induction, inflammation and wound 
healing control 
57,58
. In the physiological context, during wound repair, fibroblasts 




development in order to heal the injury. Once the wound is repaired, they undergo 
apoptosis or revert to a quiescent phenotype. In contrast, in the tumour reactive 
stroma, fibroblasts remain permanently activated as observed in fibrotic tissues, 
thus leading to a overproduction of ECM and pro-tumourigenic factors 
58
. In this 
setting, the number of activated fibroblasts, that usually express higher levels of α-
SMA, fibroblasts activation protein (FAP), vimentin, and exhibit increased ECM 
production, is substantially increased with respect to normal tissues. Although the 
molecular mechanisms that underline fibroblast recruitment at tumoural site are still 
being unravelled, it is well known that fibroblast activation is guided by several 
factors released from cancer calls. For example, it has been reported that 
transforming growth factor β (TFG-β), platelet-derived growth factor (PDGF) and 
fibroblast growth factor (FGF2) are key modulators of fibroblast activation, thus 
inducing of a desmoplastic stroma deposition 
59–61
. Actually, these factors are able 
to cause dramatic changes in CAFs, including an enhancement of their migratory 
potential and secretory phenotype. Among the molecules released by CAFs, stroma 
cell-derived factor (SDF-1) fosters tumour growth by promoting angiogenesis and 
recruiting bone marrow-derived endothelial cells 
62
. Moreover, CAFs release ECM 
degradation proteases such as MMPs, which promote motility and invasion of 
cancer cells. For instance, epithelial to mesenchymal transition (EMT) and 
invasiveness of cancer cells was found to be actively influenced by CAF-secreted 
MMP3, which directly cleaves E-cadherin 
63
. In addition, by remodelling ECM 
within the tumour microenvironment, CAFs are involved in the generation and 
maintenance of the cancer stem cell niche. In this regard, increasing evidence 
highlighted that the activation of WNT-signalling in cancer cells could be regulated 






CAFs are also crucial mediator of secondary tumour growth at metastatic sites, by 
releasing growth factors and cytokines into the circulation. In this regard, it has 
been reported that CAFs are able to foster breast cancer metastasis to the lung by 
expressing VEGFA and tenascin C 
65
. Moreover, CAF-released IL-11 was found to 





Figure 1.3. The multi-step activation of fibroblasts. Schematic representation 
of fibroblass activation from quiescent or resting fibroblast to wound healing-
associated fibroblasts or CAFs (adapted from Kalluri R. Nature Reviews 2016). 
 
In order to sustain their activated state, characterised by high proliferative rate, 
motility and intense secretion activity, CAFs undergo important metabolic 
reprogramming. Interestingly, this metabolic conversion of CAFs is able to sustain 
cancer cell metabolism to overcome the hypoxic environment within the tumoural 




to promote aerobic glycolysis in CAFs, thus increasing the production of lactate, 
fatty acid and ketone body that may support cancer cell metabolism 
67,68
. Moreover, 
this reciprocal metabolic symbiosis between cancer cells and CAFs was found to be 
associated with increased invasive and therapeutic resistance properties 
69
.  
In addition to promote tumour growth, induce EMT, foster cancer metastasis and 
provide a metabolic support to cancer cell, the secretory phenotype of activated 
CAFs exhibits immunomodulatory functions. Secretome analysis have highlighted 
that CAFs dynamically interact with several components of the tumour 
microenvironment by the secretion of chemokines, cytokines and angiogenic 
factors, including IL-4, IL-6, IL-8, IL-10 and CCL2. In this regard, CAF-secreted 
IL-4, IL-6, IL-8 are able to induce immunosuppressive myeloid differentiation. 
Moreover, in vitro evidence indicated that CAF-released CCL2 may contribute to 
create an immunosuppressive tumour microenvironment by recruiting and 
polarizing macrophages. Finally, CAFs can indirectly modulate cancer immunity 
through the promotion of angiogenesis and regulation of immune cell trans-
endothelia migration. In fact, increased levels of intercellular adhesion molecules 
(ICAM1), which acts as a docking for attraction, activation and polarization of 
immune cells, were found on the surface of activated fibroblasts.  
The CAF functions described so far highlight the great heterogeneity of this cell 
population and suggest that CAFs could co-exist in different and specific 
phenotypes, which reflect their functions. Based on increasing literature evidence it 
has been recently proposed to classify CAFs into subtypes with respect to their role 
within the tumour microenvironment, as for macrophage polarization or other 
immune cells. Hence, currently four interchanging classes of activated fibroblasts 




promoting CAFs (F2 subtype), secretory CAFs (F3 subtype) which influence 
tumour immunity and angiogenesis and ECM-producing CAFs (F4 subtype). 
However, due to the pleiotropic functions and plasticity of CAFs, it cannot be 
excluded that further studies might lead to define novel functional CAF 




Figure 1.4. A proposed classification of CAFs on the basis of their 








1.4.2. Role of CAFs in PCa 
The prostate stroma is a complex environment characterized by fibroblasts, smooth 
muscle cells (SMC), endothelial cells, immune cell types, nerves and ECM 
structures. Reciprocal interactions between prostate stromal constituents and its 
epithelium are fundamental to organogenesis. In physiological conditions, prostate 
tissue homeostasis is generally maintained by fibroblasts and SMCs, which regulate 
the proliferation of epithelial cells, the synthesis and remodelling of ECM 
structures, and are actively involved in tissue repair 
70
. Similarly, interactions 
between tumour cells and stroma components are crucial aspects of tumour mass 
formation, progression, dissemination and growth at distant sites. In PCa, as well as 
in early precancerous lesions, the stroma resembles that of wound repair, with 
massive reactive stroma formation, characterized by reduced levels of laminin and 
elevated deposition of tenascin C 
71,72
. These changes in ECM composition are 
instrumental for PCa development. Indeed, it has been experimentally proved that 
ECM isolated from PCa reactive stroma was able to improve proliferation and 
motility of LNCaP cells 
73
. Moreover, the volume of reactive stroma observed in 
Gleason 4 tumours is significantly higher than the storma of the less aggressive 
Gleason 3 
72




PCa reactive stroma largely consists of CAFs, which are functionally and 
structurally different from normal fibroblasts, and are generally characterized by 
the expression of fibroblast activation markers such as α-SMA, tenascin C, 






During prostate carcinogenesis, the number of SMCs is dramatically decreased 
within the reactive stroma, with a concomitant enhancement of CAFs 
72
.  
At present, the cell origin of CAFs is elusive. Several groups have identified 
different possible cells of origin, including resident fibroblasts, SMCs, circulating 
bone marrow-derived progenitor cells and trans-differentiation from endothelial or 
epithelial to mesenchymal cells 
76,77
. Regardless their cellular origin, several 
experimental and pathological observations have widely established their functional 
involvement in each step of PCa development, progression and dissemination 
78
. 
For instance, experimental evidence has been shown that CAFs are able to enhance 
in vitro and in vivo PCa cell proliferation, and also promote EMT, resulting in 
cancer cell invasion enhancement 
79,80
. Moreover, the massive reactive stroma 
observed in PCa is indicative of an increased ECM production and remodelling, 
caused by CAF-secreted ECM protein and proteases, such as metalloproteases 
MMPs (e.g. MMP2 and MMP9) and urokynase-type plasminogen activator, which 
induce tissue remodelling 
72
.  
In the 1999, Olumi and collaborators, described that prostate CAFs were able to 
transform non-tumourigenic prostate epithelial cells, thus providing the first 
experimental evidence of CAF involvement in PCa progression 
81
. Subsequently, 
advances in prostate CAF understanding highlighted that hepatocyte growth factors 
(HGF), insulin-like growth factors (IGF), nerve growth factors (NGF), Wnt1, 
epidermal growth factor (EGF) and fibroblasts growth factors 2 (FGF2) are key 
growth factor realised by CAFs and able to provide PCa cell growth 
78
. In addition, 
CAFs have been shown to substantially contribute to PCa progression by 
supporting both ECM deposition and turnover, and by influencing tumour cell 




EMT by CAF-released paracrine factors, including MMPs. In this regard, 
experimental models have shown that both tumour growth and spontaneous 
metastases are increased in mice subcutaneously co-injected with PCa cells and 
CAFs 
80
. More specifically, Giannoni and collaborators have recently investigated 
the mechanisms underlying CAF-mediated EMT in PCa cells, showing that CAFs 
were able to mediate the NF-Band HIF1 activation in cancer cells through the 
release of reactive oxygen species 
82
. Subsequently, HIF1 activation in cancer cells 
lead to repress miR-205 transcription 
83
, which is in turn an indirect regulator of E-
cadherin expression 
84
. As result, miR-205 repression in PCa cells was able to 
induce E-cadherin down-regulation, thus promoting EMT and cell dissemination.  
As for many tumours, CAFs were able to support cancer cell proliferation through a 
mutual metabolic reprogramming. Specifically, the limited nutrients and oxygen 
availability within the tumour microenvironment foster cancer cells to perturb CAF 
metabolism. Indeed in PCa, CAFs are forced to undergo an anaerobic glycolysis 
programme in order to produce lactate, which is extruded by CAFs through the 
monocarboxylate transporter-4 
69
. On the over hand, cancer cells increased 
monocarboxylate transporter-1 expression levels in order to improve the uptake of 
lactate 
69
, thus becoming the main proliferative boosts for cancer cell growth. 
Aging has been largely linked to the development of PCa 
85
, and it is possible that 
aging stromal components could actively contribute to PCa progression, by 
releasing tumour-promoting factors. In this regard, it has been recently shown that 
senescent prostate fibroblasts stimulate the growth of neoplastic prostate epithelium 
thought the secretion of specific factors 
86
. Moreover, in line with these 
observations, in vivo studies established that stromal regions infiltrating tumoural 
foci are enriched in senescent stromal cells 
87




collaborators have reported an interesting link between senescence and CAFs. 
Indeed, the hypoxia-induced miR-210 up-modulation in prostate fibroblasts was 
sufficient to induce senescence features in fibroblasts, and also a simultaneous 
conversion of them into activated one, with a phenotype that resembling CAFs  
88
. 
Surprisingly, activated fibroblasts overexpressing miR-210 were able to promote 




Given the relevance of aging and inflammation response, which could in part 
influence stroma reprogramming and also drive prostate carcinogenesis, emerging 
evidence highlighted a possible role of IL-6, as a key factor in the interconnection 
between fibroblast activation, senescence features and inflammation. Indeed, both 
senescent prostate epithelial cells and fibroblasts may potentially release IL-6 in the 
tumour microenvironment, thus contributing to establish or maintain a senescent 
reactive milieu able to stimulate PCa initiation and progression. In this regard, we 
recently found a substantial overlap between the transcriptomes of normal prostate 
fibroblast stimulated in vitro with IL-6 and CAFs isolated from radical 
prostatectomy samples
89
. Specifically, in order elucidated the biology and 
signalling mechanisms involved in reactive stroma formation, the gene expression 
profile of patient derived CAF and normal fibroblasts (HPF) activated in vitro with 
IL-6 or TGF-β were compared to HPF using a gene set enrichment analysis 
(GSEA). Overall, we found in all activated fibroblasts (CAFs and in vitro activated 
fibroblasts) a positive enrichment of terms related to actin cytoskeleton 
remodelling, muscle contractility and glycolysis/gluconeogenesis pathways, all 
common features of activated fibroblasts thus supporting the well-known similarity 
between CAFs and myofibroblasts 
89




sets there were also the “voltage gated cation channel activity” gene set, containing 
genes that code for calcium, sodium and potassium channels probably involved in 
the acquisition of a contractile phenotype, and the “interferon-alpha-beta 
signalling” gene set, which contains genes that are likely modulated upon cytokine 
stimulation (including IL-6, i.e. Interferon-β) (Figure 1.5- upper panel). In addition, 
genes related to ECM regulation were positively enriched in both CAFs and IL6-
activated fibroblasts but showed an opposite trend in TGF-β-HPFs (Figure 1.5- 
lower panel). However, we experimentally observed that patient derived CAF and 
in vitro activated fibroblasts with IL-6 and TGF-β were characterized by enhanced 
collagen synthesis and α-SMA expression, which are typical features of 
myofibroblasts (Figure 1.5- lower panel). 
 
 
Figure 1.5. Gene expression profiling and phenotype characterization of patient 
derived CAFs, in vitro activated fibroblasts with IL-6 and TGF- β compared to 
normal fibroblasts. (Upper left panel) Graphical representation of selected gene 


































































































































sets positively (red) or negatively (blue) enriched gene sets in CAFs (n = 3) 
compared with HPFs (n = 3). (Upper right  panel) Selected gene sets positively 
enriched in CAFs compared with HPFs. (Lower left panel) Heatmap summarizing 
significantly enriched gene sets in at least two of the evaluated comparisons (CAF vs 
HPF, IL-6-HPF vs HPF, TGF-β-HPF vs HPF, n = 3 for each group. (Lower right 
panel) Representative immunofluorescence images and immunoblotting of specific 
fibroblasts activation markers in HPFS exposed to IL-6 or TGF- β. (Adapted from 
Doldi V.et al. Oncotarget 2015). 
 
The pro-tumourigenic effect of CAFs goes beyond the direct stimulation of cancer 
cells. Actually CAFs have been shown to influence other cell types within the 
tumour microenvironment and also contribute to determine tumour resistance to 
treatments. In this regard, the ECM over-production of CAFs results in a matrix 
stiffening, which can physically impair the delivery of chemotherapeutics at the 
tumour site. In addition, it has been shown that fibronectin-rich matrix, which is 
generally produced by CAFs within the tumoural stroma, displays an anti-apoptotic 
effect in vitro on prostate cancer cell lines, promoting cell survival upon exposure 
to conventional anticancer agents and radiation 
90
. Moreover, it has been 
experimentally shown that the co-injection of CAFs and LNCaP cells in a xenograft 
model of PCa induced early angiogenesis 
91
. Finally, CAF-derived growth factors, 
such as FGF, HGF and TGF-β, and CAF-mediated ECM deregulation can create a 
tumour permissive microenvironment and potentially modulate immune infiltration 
promoting a immune suppressive milieu 
92,93
. Collectively, this evidence suggests a 
possible crucial role of CAFs in shaping the prostate tumour immunosuppressive 







1.4.3. Strategies for targeting cancer associated fibroblasts 
The ability of CAFs to promote cancer progression makes them promising 
therapeutic targets for anti-cancer strategies. Indeed, advances in understanding 
CAF role in cancer have increased the number of CAF-targeting preclinical studies, 
and a few of them have moved into clinical investigation. 
The main problem concerning CAF-targeting strategies is the lack of specific CAF 
cell surface markers, which limits the possibility to perform a direct and specific 
depletion of CAFs from the tumour microenvironment. However, multiple studies 
were focused on targeting FAP, which is a cell surface protein generally expressed 
by activated fibroblasts and actively involved in the recruitment of myofibroblasts 
at the tumoural site. In this regard, it has been recently demonstrated that either 
genetic deletion of FAP or its pharmacology inhibition, with PT630 peptide, lead to 
a robust reduction of stromagenesis, which is associated with tumour growth 
delayed in lung and colon cancer in vivo models 
94
 Moreover, a FAP-targeting 
immonotoxin has been developed for the depletion of FAP-expressing CAFs in the 
tumour microenvironment, and has been shown to induce a strong tumour 
inhibition effect in a metastatic breast cancer models 
95
. 
The potential of innovative FAP-targeting approaches have been also investigated 
in the preclinical and clinical settings. Indeed, sibrotuzumab, a humanised 
monoclonal antibody against FAP protein resulted clinically safe and able to reduce 
tumour progression 
96,97





Notably, a DNA vaccine targeting FAP displayed a moderate capability to promote 
CD8
+
 cytotoxic response against FAP-expressing CAFs, improving the uptake of 
anticancer drugs in preclinical models of colon and breast cancer 
98
. An innovative 
FAP-specific chimeric antigen receptor (CAR) T cells approach has been also 
developed and provided a specific immune response against FAP
+
 CAFs, resulting 
in moderate antitumour efficacy in mesothelioma and lung cancer preclinical 
models 
99,100
. However, severe side effects are associated to FAP-specific CARs 
approach, including lethal toxicity and cachexia, due to massive depletion of bone 
marrow stroma cells expressing FAP protein 
101,102
.  
Of note, a phase III clinical trial is currently ongoing to target CAF precursor 
infiltration in the tumour site by using bevacizumab. Specifically, bevecizumab acts 
by reducing VEGF-mediated recruitment of endothelial cells, which are a 
considerable source of CAFs within the tumour 
103
.  
Another interesting CAF-targeting strategy is aimed at reverting the CAF pro-
tumourigenic phenotype into a more tumour suppressive or quiescent state. These 
approaches are identified as “CAF normalization”. In this regard, recent studies 
performed in pancreatic ductal adenocarcinoma preclinical (PDAC) models 
highlighted that retinoic acid (ATRA) could revert fibroblast activated state and 
sequentially suppress WNT-β-catenin signaling in cancer cells or enhance the 
number of CD8
+
 T cells infiltrating the tumour site 
104,105
. Again, in PDAC models 
the treatment with calcipotriol, a vitamin D receptor ligand, induced a strong 
stromal reprogramming, thus reducing the reactive stroma deposition and 
concomitantly improving chemotherapeutic delivery into the tumour 
106
.  
Targeting activation signalling or effectors of CAFs could be a useful strategy 




several molecules have been identified as CAF activators, which are involved in 
fibroblast recruitment and activation, or CAF effectors that actively support tumour 
formation and progression. Among them, IL-6 and JAK1-STAT3 signalling has 
been largely reported to be involved in fibroblast activation 
69,107
. Recently, an 
interesting preclinical study showed that IL-6-mediated JAK1 activation in CAFs 
results in a robust ECM remodelling that promotes cancer cell invasion and 
migration. Starting from this, a novel anti-IL6 monoclonal antibody and a specific 
JAK1 inhibitor, named ruxolitinib, have entered preclinical and clinical testing in 
the cancer setting 
108,109
. In addition, in a cervical cancer preclinical model, it has 
been shown that imatinib (a clinically approved PDGFR inhibitor) was able to 
reduce tumour angiogenesis and cancer cell proliferation, by suppressing FGF2 and 
FGF7 production in CAFs 
110
. Another crucial CAF effector potentially targetable 
is SDF1, which is massively produced by FAP
+ 
CAFs. SDF1 acts through the 
stimulation of CXCR4 receptor, thus causing local immunosuppression by reducing 
CD8
+ 
T cell infiltration within the tumour site. In this context, the pharmacological 




It is known that CAFs are characterised by high secretion of several stromal 
components, growth factors and cytokines, which actively influence tumoural cell 
behaviour. In this regard, it has been reported that the pharmacological inhibition of 
mTOR-4E-BP1 pathway with somatostatine analogue (Pasireotide) in αSMA
+
 
CAFs, which overexpress somatostatin receptor (SST1), lead to the downergulation 
of CAF-secreted factors in a pancreatic preclinical model, including the key 






Finally, targeting CAF-derived ECM production and relative associated signalling 
represents another promising strategy that could potentially reduce ECM stiffness 
and favour drug delivery at tumour site. In this regard, it has been reported that 
losartan, an angiotensin inhibitor, is able to reduce CAF collagen production, thus 
improving vascular perfusion and drug delivery in pancreatic and breast tumours 
112
.  
Interestingly, the stimulation of the transmembrane smoothened (SMO) receptor by 
tumour-derived sonic hedgehog (SHH) on CAF surface leads to the activation of 
Hedgehog signalling, resulting in a increased deposition of reactive stroma. In this 
context, the treatment with IPI-929, a selective SMO inhibitor, resulted in a 
substantial reduction of CAF number within the tumour microenvironment and a 
simultaneous increase of vasculature pressure, that ultimately led to improve 
gemcitabine uptake at the tumoural site and sensitivity to VEGF inhibition 
113,114
 
(Figure 1.5).  
Collectively, the mentioned studies successfully reported that CAF depletion from 
the tumour microenvironment or their inactivation could substantially foster anti-
cancer agent delivery at the tumour site. Specifically, among the approaches 
described above, SMO and JAK1 inhibitors have emerged as a promising potential 
complement to cancer therapies and are currently tested in a considerable number 
of clinical trials 
114,115
. However, no anti-CAF therapy has been yet translated into 
the clinic. In this regard, further advances in the knowledge of CAF biology, and a 
clear understanding of intercellular interaction involving CAFs are needed to 
improve and develop efficacious therapeutic approaches based on targeting of the 






Figure 1.6. Principal strategies for CAF-directed anticancer therapy. Four 
approaches for targeting CAFs within the tumour microenvironment. (Adapted from 





















2. STUDY AIMS  
 
Tumour microenvironment is an ensemble of different cellular and structural factors, 
including vasculature and immune-related cells, fibroblasts and the extracellular matrix 
(ECM), which sustains cancer progression in an intricate network of signals hard to 
dissect and to characterize experimentally. In the prostate cancer context (PCa), cancer 
associated fibroblasts (CAF) have been shown to fuel tumour development and 
metastasis by mutually interacting with tumour cells. Recently, by comparatively 
analysing gene expression profiles of prostate CAFs, in viro activated fibroblast with 
IL-6 or TGF-β and normal fibroblasts, we found that tumour reactive fibroblasts are 
characterized by positive enrichment of gene sets related to muscle contraction, 
including voltage gated cation channel genes and ECM-remodeling proteins involved 
in cancer progression (Figure 2.1) (87). 
 
 






Ths preliminary evidence suggests a crucial role of characteristic stromal-related 
pathways involved in fibroblast conversion to a phenotype able to sustain PCa 
progression. 
On the basis of these observations, this study is aimed to test whether specific stromal 
gene signatures found to be characteristic of prostate CAFs may 1) help to develop 
novel therapeutic strategies against PCa, based on targeting the activated stroma (rather 
than tumour cells) through the use of drug repositioning and repurposing approaches, 2) 
have clinical potential as novel prognostic biomarkers in PCa. 
 
To achieve the specific aims of the thesis project:  
1) antiarrhythmic drugs, which are able to block the activity of voltage gate cation 
protein found up-modulated in CAFs, have been used in a drug-repositioning approach 
in order to counteract the myocardiocyte-like phenotype of prostate CAFs 
 
2) select ECM related genes found to be up-regulated in reactive fibroblasts were 
assessed as novel potential stromal biomarkers for risk assessment in PCa. 
 
This thesis work is expected to help undestainding the involvement of tumour adjacent 
stroma in PCa progression, generating useful information to rationally design 















Materials and Methods 
 




3. MATERIALS AND METHODS 
 
 
3.1. Cells and culture conditions  
 
3.1.1. Isolation and culture conditions of primary fibroblasts 
Primary cancer-associated fibroblasts (CAFs) and human prostate fibroblasts (HPFs) 
were isolated from prostate specimens of five PCa-bearing patients (Gleason score 4+5) 
who underwent radical prostatectomy upon informed consent, in accord with the ethics 
committee of IRCCS Istituto Nazionale dei Tumori of Milano. Intra-tumoural areas or 
non-tumoural regions of radical prostatectomy specimens were identified by an expert 
uro-pathologist of our institute, selected and cut in small pieces (3mm x 3mm) and 
digested overnight at 37°C and 5% CO2 in DMEM medium (Lonza, Basel, 
Switzerland) supplemented with 5% fetal bovine serum (FBS) (Gibco, Thermo Fisher 
Scientific, Waltham, MA, USA), 300 units/ml collagenase and 100 units/ml 
hyaluronidase solution (Stemcell Technologies Vancouver, Canada), and 1% penicillin-
streptomycin (Lonza, Basel, Switzerland). The cell suspension was centrifuged at 1,500 
g for 5 minutes. The resulting fibroblast-rich pellet was suspended and plated in 
DMEM medium (Lonza) containing 15% FBS (Gibco, Thermo Fisher Scientific), 4 
mM L-glutamine and 1% penicillin-streptomycin (Lonza). CAFs or HPFs were 
maintained in culture for 3 passages and the absence of epithelial marker expression 
was verified before being used in the experiments. All established primary cultures 
were used until the 15 passages and maintained in DMEM medium (Lonza) containing 




10% FBS (Gibco, Thermo Fisher Scientific) and 4 mM L-glutamine (Lonza). Cells 
were grown as a monolayer, at 37°C in a 5% CO2 atmosphere.  
 
3.1.2. Cell lines  
In the study the following human prostate cell lines were used: DU145, PC3 and 
WPMY-1. All cell lines were purchased from American Type Tissue Culture 
Collection (ATCC, VA, USA). DU145 cell line derives from a brain metastasis of a 
Caucasian 69-year-old PCa patient and displays an epithelial morphology. DU145 cell 
line is not hormone sensitive and does express neither androgen receptor (AR) nor the 
prostate specific antigen (PSA). PC-3 cell line derives from a bone metastasis of a 62-
year-old Caucasian PCa patient. As for DU145 cell line, it is hormone insensitive and 
presents no AR or PSA. Both DU145 and PC-3 cells are able to form adenocarcinoma 
when injected into nude mice. These PCa cell lines were maintained in RPMI-1640 
medium (Lonza) supplemented with 10% FBS (Gibco, Thermo Fisher Scientific), at 
37°C and 5% CO2.  
The prostate myofibroblast stromal cell line WPMY-1 was derived from stromal cells 
of the peripheral zone of the histologically normal adult prostate. WPMY-1 cell line 
was immortalized with SV40-large-T antigen gene, using a pRSTV plasmid construct. 
WPMY-1 cells were maintained in DMEM (Lonza) supplemented with 10% FBS 
(Gibco, Thermo Fisher Scientific). WPMY-1 cells are not able to grow when injected 
into nude mice.  
Cell lines were grown as a monolayer, at 37°C in a 5% CO2 atmosphere and routinely 
checked for mycoplasma contamination (MycoAlert Mycoplasma Detection Kit, 
Lonza). Cell lines were authenticated and periodically monitored by genetic profiling 




using short tandem repeat analysis (AmpFISTR Identifiler PCR amplification kit, 
Thermo Fisher Scientific). 
  




3.2. In vitro experiments 
 
3.2.1. Conditioned medium  
For indirect co-culture and in vivo experiments, conditioned medium (CM) was 
collected from HPFs, CAFs and WPMY-1 treated or not with antiarrhythmic drugs and 
from DU145 cells. To obtain CM, a total of 7 × 10
5




flask, treated with 1 μM of amiodarone (Hikma Pharmaceuticals, London, UK), 
1 μM verapamil (Abbott Laboratories, Chicago, USA) 1 μM nifedipine (Meda AB, 
Solna, Sweden) or flecainide (Meda AB) for 24 hours. Upon treatment, the culturing 
medium was removed, cells were washed 2 times with PBS (Lonza) and 6 ml of serum-
free medium was added. Twenty-four hours later, the CM was collected, clarified for 5 
minutes at 1,500 g and used freshly to treat PCa cells (DU145 or PC-3), to activate 
WPMY-1 or concentrated for western blotting analysis.  
 
3.2.2. Cell growth curves   
PCa cells (DU145 and PC-3) were seeded in 12-well plates (2 × 10
4 
cell/well) and after 
24 hours, cells were exposed to CM of HPFs, CM of CAFs or CM of CAF-treated with 
1 μM of amiodarone (Hikma Pharmaceuticals, London, UK), 1 μM verapamil (Abbott 
Laboratories, Chicago, USA) 1 μM nifedipine (Meda AB, Solna, Sweden) or flecainide 
(Meda AB). Upon starvation with appropriate CM, cells were harvested with Trypsin-
EDTA (Lonza) and counted at 24, 48 and 72 hours with an automated cell counter 
(Beckman, Coulter, Brea, CA, USA). All cell growth experiments were performed at 
least 3 times. 
 
 




3.2.3. Migration assay 
For migration assessment cells were seeded at 4 × 10
4
 cells/well into a 12-well culture 
plate. After 2 days, the monolayer of cells was wounded by manual scratching with a 
pipet tip, washed with PBS (Lonza), photographed (t0 point) and media were replaced 
with serum-free DMEM containing 1 μM of amiodarone (Hikma Pharmaceuticals), 1 
μM of verapamil (Abbott Laboratories), 1 μM nifedipine (Meda AB), or 1 μM 
flecainide (Meda AB) for CAFs experiments or, with CM of CAFs treated or not with 
1 μM of amiodarone (Hikma Pharmaceuticals), 1 μM of verapamil (Abbott 
Laboratories), 1 μM nifedipine (Meda AB), or 1 μM flecainide (Meda AB) for DU145 
cell migration experiments. Images of cell movement were captured at regular time 
intervals until 48 hours by using a microscope equipped with digital camera. The rate 
of cell migration was determined by using ImageJ software that measures the distance 
travelled by cells during the desired time frame. 
 
3.2.4. 3D gel collagen contraction assays 
Type I collagen from rat-tail (Sigma-Aldrich) was dissolved at 2 mg/ml in 0.1% acetic 
acid to create a stock solution. The collagen matrix was quickly prepared on ice by 
adding 6 ml of collagen stock solution to 3.6 ml of 0.1% acetic acid, 1.2 ml of 10× 
concentrated DMEM, and 1.2 ml of sodium bicarbonate solution (11.76 mg/ml) for a 
final concentration of 1 mg/ml collagen. The pH was adjusted to 7.2–7.4 by adding 0.1 
mol/l NaOH. CAFs or HPFs cells were then added to achieve a final concentration of 5 
× 10
5 
cells/ml; 500 μl of this suspension was aliquoted into each well of a 24-well 
culture plate. After 30 minutes of incubation at 37°C with 5% CO2 for polymerisation, 
the matrix in each well was overlayed with 500 μl of complete growth medium. After 




24 hours from incubation, CAFs were treated with 1 μM amiodarone (Hikma 
Pharmaceuticals), 1 μM verapamil (Abbott Laboratories), 1 μM nifedipine (Meda AB) 
or 1 μM flecainide (Meda AB), in serum free medium. Serum-free medium served as 
control. Then, the gels were mechanically released from the wall and bottom of the 
wells with a sterile spatula. Gel contraction was monitored for 48 hours and scanned by 




Figure 3. 1. Schematic representation of a 3D collagen assays 
  




3.3. Molecular biology analyses 
 
3.3.1. RNA isolation 
To perform gene expression analysis, total RNA was isolated using miRNeasy mini kit 
(Qiagen, Hilden, Germany), which combines phenol/guanidine-based lysis of cells and 
silica-membrane–based purification of total RNA. Cell pellets were homogenised 
within 700μl of QIAzol Lysis Reagent (Qiagen), a monophasic solution of phenol and 
guanidine thiocyanate, designed to facilitate cell lysis, inhibit RNases and also to 
remove most of the cellular DNA and proteins from the lysate by organic extraction. 
Tissue specimens in a deep-cold state were homogenised by using a micro-
dismembrator. Subsequently, samples were incubated at room temperature for 5 
minutes. Then, 140 μl of chloroform were added and the homogenate was separated 
into aqueous and organic phases by centrifugation (15 minutes at 12,000 g at 4°C). The 
upper aqueous phase (enriched in RNA) was transferred to a new collection tube 
avoiding the transfer of any interphase. 1.5 volumes of 100% ethanol were added and 
mixed thoroughly by pipetting in order to precipitate RNA from the aqueous phase. 
Then, 700 μl of each sample, including any precipitate, was transferred into an RNeasy 
Mini column in a 1.5 ml collection tube, and then centrifuged at ≥ 8000 g at room 
temperature for 15 seconds. The flow-through was discarded and 700 μl of Buffer 
RWT (Qiagen) were added to the columns and centrifuged for 15 seconds at ≥ 8000 g 
at room temperature. Then the columns were washed with 500 μl of Buffer RPE 
(Qiagen) by two centrifugation steps. Finally, columns were transferred to a new 1.5 ml 




tube and 30 μl of RNase-free water were pipetted directly into the column membrane 
and centrifuged for 1 minute at ≥ 8000 g to elute RNA.  
The total amount of RNA was quantified through the NanoDrop 2000c (NanoDrop, 
Thermo Fisher Scientific) spectrophotometer. The determination of nucleic acid 
concentrations is based on the absorbance at 260 nm, corrected for the extinction 
coefficient specific for RNA (=40 ng-cm/μL). Moreover, purity ratios were verified for 
each sample, by considering as “pure” a value of ~ 2.0 for 260/280 ratio (indicative of 
the presence of protein, phenol or other contaminants that absorb strongly at or near 
280 nm) and 1.8-2.0 for 260/230 ratio (the presence of residual phenol, guanidine, 
magnetic beads, carbohydrates or proteins). Quantified RNA samples were stored at -
20° C until use. 
 
3.3.2. Reverse transcription 
Reverse transcription was performed using High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems, Thermo Fisher Scientific). For each sample, the reaction was 
carried out by using 1.25 μg of total RNA in a reverse-transcription master mix 
containing 5 μl of 10x High Capacity buffer, 2 μl of dNTPs mix, 2.5 μl of Reverse 
Transcriptase, 2.5 μl of RNase Inhibitor, 5 μl of random primers and RNase-free water 
to a final volume of 50 μl (volumes for 1 reaction). A thermal cycler was used to 
perform the retrotranscription reaction as following: 60 minutes at 37°C followed by 5 
minutes at 95°C to inactivate Reverse Transcriptase. cDNA was stored ad -20°C until 
use. Detection of mRNAs was performed using appropriate assays.  
 




3.3.3. mRNA expression analysis 
mRNA quantifications were assessed by using the specific following TaqMan gene 
expression assays (Applied Biosystems, Thermo Fisher Scientific):  CACNA1H 
Hs01103527_m1, CACNB1 Hs00609503_m1, CACNB2 Hs01100744_m1, CACNB3 
Hs0016787_m1, SCN2A Hs01109871_m1, SCN1B Hs00962350_m1, KCNS3 
Hs04234270_m1, ACTA2 Hs00909449_m1 (α-SMA), FAP Hs00990806_m1, 
COL1A1 Hs00164004_m1, FSP Hs002433202_m1, CDH1 Hs00170423_m1, 
CTNNB1 Hs00355045_m1, VIMENTIN Hs05024057_m1, SNAI1 Hs00195591_m1, 
PERIOSTIN Hs01566750_m1, GAPDH Hs02786624_g1.  
GAPDH was used as endogenous control. For each sample, a mix was prepared using: 
17.5 μl of TaqMan Fast universal master mix (Applied Biosystems, Thermo Fisher 
Scientific), 1.75 μl of specific primer, 3.5 μl of diluted cDNA and RNase-free water to 
a final volume of 35 μl (volumes for 1 reaction). The amplification reaction was 
performed as following: 95°C for 15 minutes, 40 cycles of denaturation at 95°C for 15 
seconds and annealing at 55°C for 30 seconds, and a final step of extension at 72°C for 
30 seconds. Amplifications were run on the 7900HT FastReal-Time PCR System 
equipped with Sequence Detection Systems 2.4 software. Data analysis was performed 
by using RQ manager software (Applied Biosystems, Thermo Fisher Scientific) and 





 method is a comparative method that relies on comparing the differences in 
Ct (threshold cycles) values obtained with normal (reference) versus experimental 
(target) samples. Specifically, the Ct for each sample was determined. Next, the ΔCt 
value was calculated as the difference between the Ct value of the target gene and the 
Ct value of the endogenous control: ΔCt = Ct (target gene) - Ct (reference gene). In the 




next steps, the ΔΔCt value and the normalized target expression were calculated: ΔΔCt 
= ΔCt (target sample) - ΔCt (reference sample). The relative quantification (RQ), which 
allows analyse changes in gene expression in the sample of interest relative to the 
reference sample, is calculated as 2
-ΔΔCt
. 
For gene expression analysis, 150 ng of total RNA was labelled using a reverse 
transcription priming method to prime the entire length of each RNA transcript, 
including both polyA and non-polyA mRNA to provide complete and un-biased 
transcriptome coverage. This protocol efficiently generated amplified and biotinylated 
sense-stranded DNA targets, avoiding loss of specificity due to antisense strand 
interference. Data was checked for quality before being assessed on the Affymetrix 
Clariom S Human MicroArray.. On this array expression for each mRNA was assessed 
by approximately 11 probes, which were tiled throughout the transcript. The array 
provides basic gene level coverage of known genes. 
  




3.4. Biochemical analyses 
 
3.4.1. Cell viability 
The cytotoxic effect of amiodarone (Hikma Pharmaceuticals, London, UK), verapamil 
(Abbott Laboratories), nifedipine (Meda AB) or flecainide (Meda AB, Solna) was 
determined by the CellTiter96® AQueous One Solution Cell Proliferation Assay 
(MTS) (Promega Corporation, Madison Wisconsin, USA). The MTS assay is a 
colorimetric assay that allows assessing the cell viability. MTS is chemically reduced 
by cells into formazan which is soluble in tissue culture medium. The conversion of 
MTS into aqueous soluble formazan is accomplished by dehydrogenase enzymes found 
in metabolically active cells. The measurement of the absorbance of the formazan, 
which is proportional to the number of living cells, is a good indication of the viability 
of the cells and therefore of the cytotoxicity as well. The absorbance is measured at 490 
nm. Cells were plated for 24 hours in 96-well flat-bottomed microtiter plates at a 
density of 1.5 × 10
3
/50 μl, and then treated with increasing concentrations amiodarone 
(Hikma Pharmaceuticals, London, UK), verapamil (Abbott Laboratories), nifedipine 
(Meda AB) or flecainide (Meda AB, Solna) (0-5 µM) for 72 hours. At the end of the 
treatment, 20 μl of the MTS solution was added to each well and the plate was 
incubated for 3 hours in a 5% CO2 incubator at 37°C. The absorbance at 490nm was 
recorded using the POLARstar optima plate-reader (VWR International, Radnor, 
Pennsylvania, USA). The percentage of cell viability was calculated using the 
following formula: 
Viability (%) = [Abs490 treated cells/Abs490 control] x 100. 




3.4.2. Western blotting 
Protein lysates were prepared using a lysis buffer composed of 0.5 M Tris HCl pH 6.81 
(Trizma hydrochloride, Sigma-Aldrich, Merck, MA, USA), 10% sodium dodecyl 
sulphate (SDS) (Lonza) and protease/phosphatase inhibitors (25 mM sodium fluoride, 
10 μg/ml pepstatin A, 1 mM PMSF, 10 μg/ml leupeptin 30 μg/ml aprotinin, 1 mM 
sodium orthovanadate and 1 mM sodium molibdate), all purchased from Sigma-
Aldrich.  
At the appropriate time point, cells were harvested and pellets were washed in iced PBS 
(Lonza), and then homogenized for 30 minutes on ice in 100 μl of lysis buffer. In order 
to perform ex vivo evaluations, frozen-tumour specimens were homogenised by using a 
micro-dismembrator and lysed for 30 minutes on ice in 800 μl of lysis buffer. Lysates 
were clarified by centrifugation at 14,000 g for 15 minutes, cooled in ice and stored at -
20°C.  
Protein concentration was determined using spectrophotometer POLARstar OPTIMA 
(VWR International) at a wavelength of 562 nm using Pierce BCA Protein Assay Kit 
(Invitrogen, Thermo Fisher Scientifics) as colorimetric assay. To perform protein 
quantification, the Bovine Serum Albumin according to scale of dilutions from 0.01 
μg/μl to 0.05 μg/μl was used as a standard reference.  
For the assessment of secreted-proteins, CM of HPFs and CAFs treated or not with 
antiarrhythmics was clarified for 10 minutes at 1500 g and 6× concentrated by using 
Concentrator spin 5K MVCO column (Agilent Technologies, Santa Clara, CA) for 20 
minutes at 1200 g and used for protein detection.  
Cell lysates, concentrated-CM, tissue-homogenised or plasma samples were 
fractionated by SDS-polyacrylamide gel electrophoresis and then transferred into 




nitrocellulose membranes (Amersham, Pittsburgh, PA). 20 μg of protein for toral lysis 
protein and 5 μl for CM or plasma samples were loaded into gradient NuPAGE gels (4-
12%) following manufacturer’s instructions. Running buffer was prepared using: Tris-
glycine 100 ml, SDS 10% 10 ml and water to a final volume of 1 L. The electrophoretic 
run was performed at 110 V for the time necessary to allow the separation of proteins. 
Then, the gel was transferred to the nitrocellulose filter using transfer buffer composed 
of: Tris-glycine 100 ml, methanol (96%) 200 ml and water to a final volume of 1 L. 
Transfer efficacy was evaluated by Ponceau S staining (Sigma-Aldrich). Filters were 
blocked in PBS-Tween/0.5% skim milk (Sigma-Aldrich) and probed overnight with the 
appropriate primary antibodies: CACNH1 (1:500 ab128251; Abcam), CACNB1 (1:500 
ab155179; Abcam) KSCNS3 (1:500 ab34710; Abcam), SCN2A (1:500 ab65163; 
Abcam), SCN1B (1:500 ab107370; Abcam), α-SMA (1:3000, A2547 Sigma-Aldrich), 
Collagen I (1:1000 ab34710; Abcam), phospho-FAK (1:500 Y397 ab4803; Abcam), 
FAK (1:1000 ab131435; Abcam), E-cadherin (1:1000 sc-7870 H-108, Santa Cruz), β-
catenin (1:500 ab223075; Abcam), Vimentin (1:2000 ab92547; Abcam), Snail ( 1:500 
C15D3 #3879, Cell signalling Technology), MMP2 (1:200 ab92536; Abcam) Periostin 
(1:500 ab14041, Abcam), Sparc (1:1000 ON1-1 33-5500, Invitrogen), COL11A1 
(1:500 NBP1-55803; Novus Biologicals), COL11A1 (1:500 LS-B14811; Biocompare), 
Comp (1:200 NB100-2478, Novus Biologicals), β-actin (1:5000, ab8227; Abcam) or β-
tubulin (1:3000 ab6046, Abcam).  
The filters were then incubated with the respective secondary peroxidase-linked whole 
antibodies (GE healthcare, UK) 1 h at room temperature. Bound antibodies were 
detected using the Novex ECL, HRP Chemiluminescent substrate Reagent Kit (Life 
Technologies, Thermo Fisher Scientific) and filters were auto-radiographed.  




Band quantification was performed taking advantage of the ImageJ software. For the 
preparation of figures, the original western blots were cropped to generate the figure 
panels with the relevant lanes. Cropped images were then subjected to uniform image 
enhancement of contrast and brightness. Molecular weights were determined using the 
colorimetric SeeBlue Plus Protein Standard (Life Technologies, Thermo Fisher 




To perform immunofluorescence analysis, CAFs were seeded at 6 × 10
4
 cell/well in a 
6-well plate containing a coverslips suitable for microscopy. After 24 hours, CAFs 
were treated with 1 μM amiodarone (Hikma Pharmaceuticals), 1 μM verapamil (Abbott 
Laboratories), 1 μM nifedipine (Meda AB) or 1 μM flecainide (Meda AB), in serum 
free medium. Forty-eight hours later cells were rinsed in PBS (Lonza) and fixed in 4% 
formaldehyde dissolved in PBS for 10 minutes. After washing with PBS, cells were 
permeabilised with 1:1 Acetone / Methanol solution.  After 2 washes in PBS, cells were 
probed with primary antibodies for phospho-FAK (1:200 Y397 ab4803; Abcam) 
diluted in antibody diluent (Dako Ab Diluent from Agilent Technologies) for 1 hour at 
room temperature. After washing with PBS, an Alexa Fluor594-labeled secondary 
antibody Thermo Fisher Scientific) was used to incubate cells for 1 hour at room 
temperature. Actin filaments were stained using phalloidin-conjugated-Fluor488 dye 
and nuclei were stained with DAPI (Invitrogen, Thermo Fisher Scientific) and images 
were acquired by Nikon Eclipse E600 microscope using ACT-1 software (Nikon).  





3.4.4. Cell cycle analysis  
For cell cycle evaluation, DU145 were seeded in 6 well plates (6× 10
4 
cell/well) and 
after 24 hours, cells were exposed to CM of HPFs, CM of CAFs or CM of CAF-treated 
with 1 μM of amiodarone (Hikma Pharmaceuticals, London, UK), 1 μM verapamil 
(Abbott Laboratories, Chicago, USA) 1 μM nifedipine (Meda AB, Solna, Sweden) or 
flecainide (Meda AB). 72-hours upon starvation with appropriate CM, cells were 
harvested with Trypsin-EDTA (Lonza) and fixed in cold 70% ethanol solution for 30 
minutes on ice. Cells were washed in PBS 1X (Lonza) and resuspended in the staining 
solution composed of PBS with 100 ng/µl of RNase A (Sigma-Aldrich) and 50 μg/mL 
Propidium Iodide (Sigma-Aldrich). Stained cells were incubated overnight at 4°C. The 
cycle distribution was detected by the BD Accuri C6 Flow Cytometer. All cell cycle 
analysis experiments were performed at least 2 times. 
 
3.4.5. Immunohistochemistry 
For Ki-67 immunohistochemical analysis, tumours were removed, formalin-fixed and 
paraffin embedded. 4-μm tumour sections were deparaffinized in xylene, rehydrated 
through graded alcohols to water, and subjected to immunohistochemical analysis using 
the following antibody: anti-mouse monoclonal antibody Ki-67 (8D5#9449, Cell 
Signaling) at the dilution of 1:100. Nuclei were counterstained with hematoxylin. 
For prtiostine staining, formalin-fixed, paraffin-embedded (FFPE) specimens from 
radical prostatectomies were obtained from the archive of the IRCCS Istituto Nazionale 
dei Tumori di Milano, following ethical approval procedures. Tissue sections of 4-μm 
were subjected to automated immunohistochemistry on Autostainer Link 48 instrument 




(Agilent Technologies) using EnVisionFLEX+ Target Retrieval Solution, high pH 
(Dako, Agilent Technologies) detection system according to manufacturer’s 
instructions. Briefly, tissue sections of 4-μm were deparaffinised in xylene and heat-
induced epitope retrieval was performed in EnVisionFLEX+ Target Retrieval Solution, 
high pH (Dako, Agilent Technologies) for 30 minutes at 97°C. Periostin was identified 
using the anti-POSTN antibody (ab14041, Abcam) at the dilution of 1:1000. Adjacent 
sections were stained with hematoxylin and eosin for anatomical reference.  
 
3.4.6. Enzyme-linked immunosorbent assay  
Periostin, Sparc, Comp and Col10a plasma concentration was determined by solid 
phase sandwich enzyme-linked immunosorbent assays (ELISA), according to 
manufacturer’s instructions. The following ELISA tests were used: Human Periostin 
ELISA kit (EHPOSTN; Invitrogen, Thermo Fisher Scientific), Human SPARC 
Quantikine ELISA (DSP00, R&D System), Human COMP Quantikine ELISA 
(DCMP0, R&D System), Human Collagen Alpha -1(X) Chain (COL10A1) ELISA kit 
(CSB-EL005715HU, Cusabio), Collagen Type XI Alpha 1 (COL11a1) ELISA kit 
(SEC157Hu, Cloud-Clone Corporation).    
To obtain plasma sample, whole blood was collected in anticoagulant-tubs (BD 
Vacutainer™ Heparin Plasma Tubes,) and plasma was immediately separated by 
centrifugation at 2,200 g for 20 minutes by using a refrigerated centrifuge at 4°C. The 
supernatants obtained were further clarified for 10 minutes at 2,200 g, and stored at -
80°C. Plasma samples were tested in duplicate, according to the manufacturer’s 
instructions. The coloured product generated by the enzyme activity was detected by 
the plate-reader POLARstar optima (VWR International) at 450 nm. 










3.5. In vivo experiments 
Animal studies were performed in accordance with guidelines of animal care protocols 
approved by ethics committee for animal experimentation of IRCCS Istituto Nazionale 
dei Tumori of Milano. Male SCID mice were purchased from Charles River 
Laboratories and housed in specific pathogen-free conditions.   
Prostate tumour xenografts were generated by subcutaneous injection of 1 × 10
7 
DU145 
cells in the right flank of SCID mice and when tumours reached ~100 mm
3
 (Width2 x 
Length/2), mice were randomly assigned to control or treatment groups (n=6). 
Subsequently, mice were intratumourally treated (5 consecutive days for 2 weeks) with 
250 μl of CM of WPMY-1, activated-WPMY-1 exposed or not to 1 μM amiodarone 
(Hikma Pharmaceuticals), 1 μM verapamil (Abbott Laboratories), 1 μM nifedipine 
(Meda AB) or 1 μM flecainide (Meda AB) and serum-free medium as control.  
At two different time points (after 1 week and at the end of the treatments) 
subcutaneous tumours were harvested in order to investigate the impact on tumour 
plasticity by analysing the expression of specific epithelial-to-mesenchymal transition 
markers.  
 
3.6. Bioinformatics analyses 
For gene expression profiling, RNA samples were processed for microarray hybridation 
by Functional Genomics core facility at Fondazione IRCCS Istituto Nazionale dei 
Tumori, Milano Italy. RNA was reverse transcribed, labeled and amplified using the 
expression profiling tool human Clariom™ S Assay according to manufacturer’s 
protocol. Raw data were normalized according to the RMA algorithm of the oligo 




Bioconductor package. Probes not assigned to an official gene symbol were removed, 
while for probes mapping on the same gene symbol, the one with the highest variance 
value was selected. Besides, to reduce intervariability among samples, batch effects we 
adjusted with a linear model, using ComBat function of the sva package. Differential 
expression was estimated both in terms of fold change (FC) and t-value (paired t-test), 
using the limma Bioconductor package. Statistical significance was provided in terms 
of False Discovery Rate (FDR) taking into account the adjustment for multiple 
hypotheses testing, and considering a threshold of 0.05. All analyses were performed 
using the computing microenvironment R. 
A single-sample GSEA (ssGSEA) was performed on normalized data, using Hallmark 
collection of MSigDB database 
116
. This approach scores each individual sample 
against gene sets belonging to the collection. In this way, hierarchical clustering was 
represented in a heatmap, by plotting the normalized enrichment score (NES) and using 
Spearman correlation as a distance measure and average as a linkage method.  
 
3.7. Statistical analyses 
Data are presented as mean values ± standard deviation from at least three independent 
experiments. Two-tailed Students’t test or chi-squared test were chosen as statistical 
analysis and performed by Prism GraphPad software. P-value <0.05 were considered 
statistically significant. 




















4. RESULTS I: Drug repositioning approaches to counteract the 
activated phenotype of CAFs and affect CAF-PCa cell interplay  
 
The first aim of the study is to evaluate the biological effects of cation channel 
inhibitors on CAF activated state. In the clinical routine, cation channels inhibitors, 
such as antiarrhythmics, are used to restore the normal rhythm and heart conduction 
in patients with cardiac arrhythmias 
117
. Starting from our preliminary observation 
highlighting the up-modulation of ion channels in prostate CAFs compared to HPFs 
89
, we assumed to use antiarrhythmic drugs, in a drug-repositioning approach, to 
target the myocardiocyte-like phenotype of prostate CAFs, with the final aim of 
interrupting the crosstalk between CAFs and PCa (Figure 4.1). 
 
 
Figure 4.1. Schematic representation of drug-repositioning approach 
 
Following this strategy, human primary fibroblasts were used to perform the 
experiments of the preclinical part of the project. Specifically, CAFs were isolated 
and established from tumoural areas of radical prostatectomy specimens and, for 
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comparison normal prostate fibroblasts (HPF) were obtained from non-tumoural 
stromal areas of the same clinical sample. In addition, for further biological 
functional validation, we used the prostate stromal cell line WPMY-1, purchased 
from ATCC.  
Experimentally, we exposed activated fibroblasts to sub-toxic doses of 
antiarrhythmics and assessed the effect of the drugs on i) CAF activated state, and on 






4.1. Evaluation of the relevance of ion channels on CAF activated state 
 
4.1.1. Validation of gene expression results 
Before  investigating the effect of cation channel inhibitors on CAF activated state, 
the very first step of the study was the in silico and experimental validation of our 
gene expression data indicating up-regulation of cation channel genes in prostate 
CAFs.  
Initially, we evaluated the expression levels of cation channels in publicly available 
gene expression datasets. In accordance with our observation, the analysis of 
GSE86260 dataset highlighted the significant enrichment of voltage-gated cation 
channel activity and voltage potassium activity gene sets (Figure 4.2) in genes up-
modulated in prostate CAFs compared to normal fibroblasts, thus suggesting the 







Figure 4.2. Evaluation of ion channel expression levels in GSE86260 
database. Gens sets significantly up-modulated in seven CAFs samples 
isolated from radical prostatectomy with respect to normal fibroblast are 
highlighted in red (Log2 FDR ≥2), NES (normalised enrichment scores).  
 
In a next step, we carried out a biological validation of our gene expression data. 
Specifically, the expression levels of selected ion channels belonging to the voltage-
gated channel activity gene set (CACNA1H, CACNB1-3, SCN2A, SCAN1B, and 
KCNS3) were analysed by qRT-PCR and western blotting in an independent panel of 
paired CAFs and normal fibroblasts (HPFs) isolated from three patients who 
underwent radical prostatectomy at our Institute. Consistent with our preliminary 
observations, we confirmed that ion channels, especially sodium (SCN2A, SCN1B) 
and calcium channels (CACNAH1, CACNB1-3), were up-regulated both at the 
mRNA and protein level in the independent panel of CAFs, compared to paired 
HPFs (Figure 4.3). In contrast, despite KCNS3 mRNA was found to be down-
modulate in our panel of CAFs compared to HPFs, however we confirmed its up-
































Figure 4.3. Validation of expression data obtained from GSEA analysis. (Upper 
panel) The expression levels of CACNA1H, CACNB1, CACNB3, SCN2A, 
SCN1B, and KCNS3 were evaluated in an independent setting of three paired CAFs 
and HPFs. Data are reported as relative expression compared to HPF. and are 







































































representative of three independent experiments. (Lower panel left) Western 
blotting analysis showing selected ion channel protein levels in paired 
CAF#1/HPF#1 and CAF#2/HPF#2 samples. (Lower panel right) The bar plot 
reports quantification of western blot. Densitometry data are reported as raw 
normalized values (arbitrary units) towards the loading control (β-actin). The level 
of significance was represented as *p<0.05, **p<0.01, ***p<0.005, Student’s t-test. 
 
 
Overall, we confirmed our preliminary findings regarding the up-modulation of 
cation channels in prostate CAFs, by analysing public data and assessing the 
expression levels of cation channels in an independent panel of three CAF derived 
from radical prostatectomy samples collected in our Institute. Considering this 
preliminary observation, we were prompted to study the effects of ion channels 
inhibitions on CAF activated state.  
 
4.1.2. “In vitro” activation of fibroblasts confirms the up-modulation of ion 
channels 
In order to investigate the relevance of cation channels in fibroblasts activated 
phenotype, we performed an in vitro activation of fibroblasts by treating HPFs with 
conditioned medium (CM) of DU145 PCa cells with the aim to mimic the 
pathological environment, in which cancer cells condition the behaviour of normal 
stromal cells. Specifically, HPFs were exposed for 48 hours to CM of DU145 cells 
and the activated state was assessed by the evaluation of fibroblast activation 
markers. Additionally, to elucidate the involvement of ion channels in the shift from 
the inactivated to the activated phenotype, ion channels expression levels were 
investigated as well. qRT-PCR analysis showed that two sets of HPFs (HPF#1 and 










Figure 4.4. Increased activation marker expression levels in HPFs exposed 
to CM of DU145 cells. The expression levels of α-SMA, FAP, COL1A1 and 
FSP were evaluated in HPFs upon exposure to activation stimuli (Conditioned 
medium of DU145 cells). Data are reported as relative expression compared to 
untreated fibroblasts and are representative of three independent experiments 
The level of significance was represented as * p<0.05, ** p<0.01, *** p<0.005, 
Student’s t-test. 
 
Similarly, once assessed the activated state of treated HPFs, we investigated the 
expression levels of selected ion channels. Interestingly, qRT-PCR analysis revealed 
a marked up-regulation of CACNAH1, CACNB1, CACNB3, SCN2A, SCN2B and 
KCNS3 in HPFs upon exposure to CM of DU145 cells (Figure 4.5). 
 


















































Figure 4.5. Evaluation of ion channel expression levels in in vitro 
activated HPFs. The expression levels of CACNAH1, CACNB1, CACNB3, 
SCN2A, SCN1B and KCNS3 were evaluated in HPFs upon exposure to 
activation stimuli (conditioned medium of DU145 cells). Data are reported as 
relative expression compared to untreated fibroblasts and are representative 
of three independent experiments. The level of significance was represented 
as * p<0.05, ** p<0.01, *** p<0.005, Student’s t-test. 
 
These results indicated that the activation state of fibroblasts, assessed by the up-
modulation of specific fibroblasts activation markers, was associated with the 
concomitant up-modulation of cation channels. This evidence suggests that ion 
channels were actively involved in fibroblast activation and their up-modulation 
could represent a relevant step within the complex fibroblast activation process 
during tumourigenesis. 
  































































































4.2. Evaluation of antiarrhythmic effects of CAF activated state  
 
4.2.1. Antiarrhythmic treatment of CAFs (experimental conditions)  
Once validated the up-regulation of cation channels in CAFs and their involvement 
in fibroblasts phenoconversion from an inactivated to an activated state, we sub-
sequentially set up dose-response experiment in order to identify sub-toxic 
antiarrhythmic concentrations for treating CAFs. Following this strategy, we 
identified a panel of four antiarrhythmic drugs able to inhibit the activity of those 
cation channels that we found up-regulated in CAFs (Table 4.1).  
 
 
Table 4.2. List of ion channels up-modulated in CAFs and 




Specifically, we performed all the experiments by using the following 

























KCNH2 and KCNQ2); verapamil and nifedipine to block calcium channels 
(CACNA1H and CACNB1-3); and flecainide to counteract the activity of sodium 
channels (SCN2A and SCN1B).  
Initially, we tested different doses of each drug to identify the range of concentration 
appropriate to treat CAFs, without impact on cells viability. In details, we exposed 
CAFs to antiarrhythmics for 72 hours, with concentrations ranging from 0.1 µM to 
5.0 µM. MTS assay results revealed that antiarrhythmics did not display major 
cytotoxic effects on a set of two different CAFs (CAF#1 and CAF#2) isolated from 
clinical samples (Figure 4.6). For this reason, we arbitrarily selected the sub-toxic 
concentration of 1 µM for each drug to perform all the experiments aimed at 







Figure 4.6. Antiarrhythmic drugs cytotoxic effects on CAFs. MTS assay of two 
panel of prostate CAFs derived from clinical samples (CAF#1 and CAF#2) exposed to 
amiodarone, verapamil nifedipine or flecainide for 72 hours. The cell viability 
following the indicated drug doses is reported as percentage of untreated cells. Data 
reported are representative of three independent experiments. 
 
 
4.2.2. Antiarrhythmics treatment resulted in morphological changes and partial 
modulation of activation markers in CAFs. 
Once identified the sub-toxic antiarrhythmic concentrations suitable for treating 
CAFs, we performed several experiments in order to assess whether antiarrhythmics 
were able to counteract the activated phenotype of CAFs. As first, we evaluated the 



































































































reflect the activate state of CAFs. In details, the treatment of CAFs with sub-toxic 
doses (1 µM) of antiarrhythmics (amiodarone, verapamil, nifedipine or flecainide) 
for 48 hours resulted in marked morphological changes, which was particularly 
evident when CAFs where exposed to 1 µM of amiodarone. Morphologically 
speaking, as showed in the photomicrographs, amiodarone-treated CAFs exhibit a 
more elongated and thin shape, compared to control (Figure 4.7). 
 
 
Figure 4.7. Antiarrhythmic drugs induced morphological changes in CAFs. 
Representative phase contrast microscopy images showing morphological changes in CAFs 
exposed to sub-toxic doses of antiarrhythmic drugs (scale 100 µm). White arrows 
highlighted flattened and enlarged cells, with visible stress fibres. 
 
 
The effect of antiarrhythmic treatment of CAFs activate state was evaluated in terms 
of expression levels of specific activation markers. Specifically, upon the treatment 
of CAFs with three selected sub-toxic doses of antiarrhythmics (1 µM, 2.5 µM and 5 
µM) for 48 hours, α-SMA and Col1a1 levels resulted partially decreased, which was 
particularly appreciable upon the treatment with amiodarone or verapamil, in a dose-












Figure 4.8. Antiarrhythmic drugs induced a partially down-modulation of 
specific fibroblast activation markers in a dose-dependent manner. Western 
blot analysis showing α-SMA and Col1a1 protein amount in CAFs treated for 48 
hours with three sub-toxical doses of antiarrhythmics (1 µM, 2.5 µM and 5 
µM), normalized to β-tubulin. The bar plot reports quantification of western 
blot. Densitometry data are reported as raw normalized values (arbitrary units) 
towards the loading control (β-tubulin). 
 
 
Overall, the treatment of CAFs with sub-toxic doses of antiarrhythmic drugs was 
able to perturb fibroblasts morphology and partially reverts the activated state of 
CAFs, in a dose and drug-dependent manner, as indicated by the moderate down-
modulation of fibroblasts activation markers, expecially upon the treatment with 



































































































































4.2.3. Antiarrhythmic reduced CAF motility and FAK phosphorylation 
Considering the relevance of cell migration and extracellular matrix remodelling 
properties of activated fibroblasts, we evaluated the effect of antiarrhythmics on CAF 
migration potential by performing the traditional scratch assay. Specifically, CAFs 
were seeded and the monolayer of cells were wounded by manual scratching with a 
pipet tip, washed with PBS, photographed (0 h point) and media were replaced with 
serum-free-DMEM containing sub-toxic doses (1 µM) of amiodarone, verapamil, 
nifedipine or flecainide. Images of cell movement were captured at 24 hours. As 
indicated in the representative photomicrographs and in the bar plot, treated CAFs 
showed a significantly delayed closure of the wound than untreated cells, suggesting 












Figure 4.9. Antiarrhythmics impair CAF migratory capability. (Upper 
panel) Representative phase contrast microscopy images showing migration 
rate of CAFs exposed to sub-toxic doses of antiarrhythmic drugs (scale 100 
µm). The dotted lines define the areas lacking cells. (Lower panel) Bar plots 
showing the wound-healing rate of CAFs assessed by scratch assay. Data are 
reported as wound healing ratio at 24 h compared to 0 h point and are 
representative of three independent experiments. The level of significance 
was represented as * p<0.05, ** p<0.01, Student’s t-test. 
 
 
Moreover, in accordance with the observed reduced migration rate, FAK signalling 
was found down-modulated in CAFs exposed to antiarrhythmic drugs. 
Immunofluorescence staining for p-FAK revealed less reactivity and a marked 
delocalization of the protein from the focal contacts, especially when CAFs were 
treated with verapamil (Figure 4.10). Similarly, as showed in the immunoblotting, 
the treatment with antiarrhythmics induced a marked reduction of p-FAK fraction 
protein levels (Figure 4.10). Overall, this experimental evidence further suggests that 
antiarrhythmic cation channel inhibition could effectively hinder CAF motility. 












































Figure 4.10. Antiarrhythmics hinder focal adhesion formation. (Upper panel) 
Representative immunofluorescence images showing reduction of p-FAK staining (red) and 
delocalization from cell membrane in verapamil-treated CAFs. Actin (green) was used to 
stain focal adhesion and DAPI (blue) to stain nuclei (scale bar 10 µm). (Lower panel left) 
Western blotting analysis showing p-FAK protein amount in antiarrhythmic treated CAFs. 
FAK and β-tubulin was used as loading control, respectively. (Lower panel right) The bar 
plot reports quantification of western blot. Densitometry data are reported as raw normalized 
values (arbitrary units) towards the loading control (β-tubulin).  
 



















































Consistent with their role in the tumour microenvironment, CAF pro-tumourigenic 
activity is also related to their capability to remodel the extracellular matrix (ECM) 
and create a desmoplastic environment, thus promoting tumour dissemination 
118
. 
Considering this setting, we tested whether CAF ion channels inhibition, by using 
antiarrhythmics, would result in a reduction of ECM remodelling potential of CAFs. 
ECM remodelling ability could be recapitulated by cell capability to stress a 3D 
collagen gel, in which cells were seeded and then treated with antiarrhythmics. Cells 
that were characterised by a high remodelling capability display a greater gel 
contraction rate. Antiarrhythmic treatment of CAFs determined a significant 
reduction of their ability to cause 3D collagen gel stress compared to untreated 
CAFs, especially upon treatment with sub-toxic doses of verapamil, nifedipine or 
flecainide. Considering that this is a crucial feature of CAFs, this result suggests the 
involvement on ion channels in CAF ECM remodelling and indicated the possibility 










































Figure 4. 11. Antiarrhythmics reduce CAF potential to remodel ECM. (Upper 
panel) Representative images showing 3D collagen gel rate remodelling of CAFs 
exposed to sub-toxic doses of antiarrhythmic drugs. (Lower panel) Bar plots 
showing the ECM remodelling ratio of treated CAFs assessed by 3D collagen gel 
assay. Data are reported as ECM remodelling ratio at 48 h compared to 0 h point 
and are representative of three independent experiments The level of significance 




4.2.5. Antiarrhythmic effect on CAF gene expression profile. 
With the aim of studying the effects of antiarrhythmics on CAF transcriptome, gene 
expression profiling was conducted. For this experiment, we sought to focus on those 
antiarrhythmics that showed, in our hands, a grater capability to impact on ECM 
remodelling process mediated by CAFs (Figure 4.11), and a prominent reduction of 
CAF migration potential (Figure 4.9). Specifically, a panel of three different CAFs 
were exposed to nifedipine and flecainide for 48 hours. Upon the treatment, the total 
RNA was isolated and analysed using Clariom S array. For comparative purposes, 
we included matched HPFs isolated from the same patients. 








































As shown in figure 4.12, the principal component analysis (PCA) identified three 
different clusters of samples, separated along the first principal component (PC1). 
Specifically, we observed a cluster composed of CAFs and a completely distinct 
cluster characterized by HPFs. More interestingly, although close to the CAF cluster, 
a third group represented by CAFs treated with antiarrhythmics were identified. In 
addition, the different shaping schemes applied to the samples highlighted that the 
cluster separation was not associated with the patient. These findings further suggest 
that antiarrhythmics were able to perturb CAFs activated phenotype by inducing 
gene expression changes that make them resemble to HPFs. 
 
 
Figure 4. 12. PCA plot of gene expression data from antiarrhythmics-
treated CAFs. PCA was performed on gene expression data from a panel of 
three CAF primary cultures treated or not with nifedipine or flecainide and 
matched HPFs (colour code: HPFs grey, CAFs brown, CAFs treated with 
nifedipine-yellow-CAF_N, CAFs treated with flecainide orange-CAF_F). Batch 
effects were removed by applying combat algorithm. Samples were plotted 
along the first two principal components (PCs). Different colouring schemes 





In addition, in order to compare gene expression changes induced by antiarrhythmics 
and highlight commonalities and differences among fibroblast profiles, we 
performed a single sample gene set enriched analysis (ssGSEA) by using Hallmark 
collection from The Molecular Signatures Database (MSigDB) (https://www.gsea-
msigdb.org/gsea/msigdb/collections.jsp). The Hallmark collection summarizes and 
represents specific well-defined and relevant biological states or processes, and the 
major molecular mechanisms of cells. These gene sets were generated by a 
computational strategy, based on the identification of genes shared by other 
collections but that show a coherent behaviour (116). In line with this evidence, we 
selected Hallmarks since they reduce noise and redundancy, providing a more 
refined and concise inputs of the molecular mechanisms implicated in fibroblasts 
activation profile.  
As shown in figure 4.13, the unsupervised clustering grouped 2 major categories 
defined as “normal-like” and “tumour-like” groups. Specifically, the “normal-like” 
cluster is mainly represented by HPFs and the “tumour-like” is composed of CAF 
samples. Surprisingly, the antiarrhythmic treated-CAF samples are spread across the 
2 groups, independently from the patient origin and treatment, thus indicating that 
the treatments are able to perturb CAFs expression profile and in part resembling of 






Figure 4.13. Heatmap of ssGSEA on hallmark canonical gene sets. The 
unsupervised hierarchical clustering of columns grouped HPFs, antiarrhythmic-
treated CAFs, and CAFs in 2 major categories based on their differential expression 
levels of genes belonged to hallmark collection. Each row represents a gene set, 
while each column represents a different biological sample. The first line annotation 
indicates fibroblasts phenotype (colour code: HPFs grey, CAFs brown, CAFs 
treated with nifedipine-yellow-CAF_N, CAFs treated with flecainide orange-
CAF_F). The second line depicts patient origin (colour code: patient 1 black, 
patient 2 red, patient 3 green). Red-white-blue colormap is used to visualize the 
magnitude of the normalized enrichment score (NES) value of the specific signature 
in the specific sample, where red is up-regulation and blue is down-regulation. 
 
Moreover, a classical GSEA approach was performed on the same collection. Only 
significant (FDR threshold < 0.05) comparisons with the same magnitude among all 
the three contrasts were considered. To share light on the genes involved in the 
signatures of interest, the intersection of the leading edges of each single contrast 






The GSEA revealed interesting commonalities between HPFs and treated CAFs 
compared to CAFs that belong to the normal-like cluster. Especially regarding the 
down-modulation of genes implicated in epithelial to mesenchymal transition, 
glycolysis, hypoxia, and protein secretion pathways (Figure 4.14). Contrarily, CAFs 
showed an induction of the abovementioned gene sets, which completely reflect their 
role in the tumour microenvironment. Overall, the expression landscape of treated 
CAFs indicated the shift of specific pathways, suggesting that nifedipine and 
flecainide were able to affect CAFs phenotype by inducing the modulation of crucial 






Figure 4.14. GSEA highlighted crucial communities between 
antiarrhythmic-treated CAFs and HPFs. Heatmap representing gene sets 
from hallmark collection with significant modulation. The normalized 







4.3. Evaluation of antiarrhythmic drug effect on CAF-PCa cell interplay 
 
In order to investigate whether the inhibition of CAF cation channel activity could 
affect CAF pro-tumoural boost, co-culture approaches for studying the in vitro 
interaction between CAFs and PCa cells were carried out. In this regard, indirect co-
culture experiments, which represent the relevant in vitro techniques to study 
paracrine interactions, were set up to test the effects of antiarrhythmics treatment on 
CAF-PCa cell interplay. Specifically, conditioned media (CM) of antiarrhythmics-
treated CAFs were used to culture PCa cells, and the effects on PCa cells were 
evaluated. CAFs were initially treated with sub-toxic doses of antiarrhythmics 
(amiodarone, verapamil, nifedipine or flecainide) for 48 hours, then culture media 
were switched to fresh serum-free medium and treated CAFs were incubated for 
additional 24 hours. Then CM were harvested, clarified by centrifugation, and used 
freshly to culture PCa cell lines (DU145 or PC-3). CAF-CM effects were evaluated 
in terms of cell growth and prostate cancer cell plasticity (Figure 4.15). 
  
Figure 4.15. Schematic representation of CAF-PCa indirect co-culture 
system based on the use of conditioned medium. 
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4.3.1. CM from CAFs treated with antiarrhythmics affect PCa cell growth and cell 
cycle distribution 
By using a indirect co-culture approach, PCa cells (DU145 and PC-3) were exposed 
to CM of CAFs pre-treated or not with sub-toxic doses of antiarrhythmics and 
cultured until 72 hours. The number of cells was evaluated by cell counting. As 
showed in figure 4.16, the CM of CAFs displayed a slightly promoting effect on PCa 
cell growth compared to control, which was more appreciable in DU145 than PC-3 
cells. In contrast, CM from HPFs induced a marked inhibition of PCa cell growth in 
both cell lines. Surprisingly, the treatment of CAFs with antiarrhythmics reduced 
their capability to sustain PCa proliferation and let them acquire a more growth-

















































Figure 4.16. Antiarrhythmics-treated CAFs recapitulate HPFs capability to 
suppress PCa cell growth. Cell growth evaluation of DU145 (upper panel) and 
PC-3 (lower panel) cells cultured with CM of CAFs treated or not with 
antiarrhythmics, or CM of HPF at different time points (24, 48, 72 hours). Data 
are representative of three independent experiments. The level of significance 
was represented as * p<0.05, ** p<0.01, Student’s t test. 
 
In addition, a cell cycle analysis has been performed  in order to assess whether 
CM of treated CAFs could affect PCa cell cycle phase distribution. 
Specifically, DU145 cells were exposed to CM of CAFs pre-treated or not with 
sub-toxic doses of antiarrhythmics and cultured until 72 hours. As shown in 
figure 4.17, DU145 cells exposed to CM of antiarrhythmic treated-CAFs or 
CM of HPFs displayed a significantly higher percentage of cells in the 
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in the percentage of cells in S phase. In contrast, the treatment with CM of 




Figure 4. 17. Antiarrhythmics-treated CAFs recapitulate HPFs capability to 
perturb DU145 cell cycle phase distribution. Cell cycle phase distribution of DU145 
cells cultured with CM of CAFs treated or not with antiarrhythmics, or CM of HPF at 
72 hours until treatment. Data are representative of two independent experiments. The 
































































4.3.2. DU145 cells exposed to CM of antiarrhythmics-treated CAFs displayed a 
more epithelial-like phenotype 
 
To further investigate the effect of antiarrhythmics on CAF-PCa cell interplay, we 
evaluated CAF ability to remodel DU145 cell plasticity. Specifically, upon exposure 
to CM of CAFs treated or not with antiarrhythmics, the number of DU145 cells 
displaying a polygonal shape and cluster organization or a elongated 
morphology/spindle-like shape was assessed. Morphologically speaking, 
photomicrographs and bar plot quantification showed an increase of individual 
spreading/elongated cells upon exposure of DU145 cells to CM of CAFs, suggesting 
the acquisition of a more mesenchymal-like phenotype. In contrast, the number of 
spreading DU145 cells was significantly reduced upon culturing with 
antiarrhythmics-treated CAF CM, indicating that antiarrhythmics were able to reduce 
CAF-induced DU145 cell plasticity boost. These preliminary observations suggest 
that antiarrhythmic treatment could affect the ability of CAFs to promote the 










Figure 4. 18. Antiarrhythmics reduce CAF capability to induce plasticity 
in DU145 cells. (Upper panel) Representative phase contrast microscopy 
DU145 CM CAF 
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images showing morphological changes of DU145 cells cultured with CM 
CAFs treated or not with antiarrhythmics (scale bar 100 μm). (Lower panel) 
Bar plot indicating the number of DU145 cells with a spreading-elongated cell 
morphology obtained by counting five fields for each experimental condition 
and compared to untreated. Data are representative of three independent 




4.3.3. Antiarrhythmics reduce CAF-induced EMT in PCa cells 
It has been largely reported that CAFs are able to enhance malignancy features of 
PCa cells, promoting the switch from an epithelial-like phenotype to a more 
mesenchymal one 
119
. In order to verify whether antiarrhythmics treatment of CAFs 
was able to revert such pro-tumoural effects, we performed qRT-PCR evaluation of 
different EMT-related markers, such as CHD1 (E-cadherin), CTNNB1 (β-catenin), 
VIMENTIN and SNAI1 (Snail) in DU145 and PC3 cells cultured with CM of CAFs 
(CM-CAF), CM of CAFs treated with antiarrhythmics (CM antiarrhythmic-CAF) or 
CM of HPFs (CM-HPFs). Accordingly, we observed that CM-CAF was able to 
down-modulate the epithelial markers CDH1 and CTNNB1 in PCa cells, inducing a 
more mesenchymal phenotype as assessed by the up-modulation of VIMENTIN and 
SNAI1. The treatment of CAFs with antiarrhythmics partially reverted such EMT-
promoting effect on PCa cells. Specifically, qRT-PCR analysis showed that the CM 
from antiarrhythmic-CAFs was less able to down-modulate CDH1 in DU145 and 
PC-3 cells, and in some cases it even increased it, partially recapitulating the effect 
observed with the CM-HPFs, which is recognised has tumour-suppressive features 
120
. More interestingly, western blot analysis on DU145 cells confirmed the down-





Vimentin and Snail (SNAIL1) upon exposure to the different aforementioned stimuli 
(Figure 4.19),. These results suggest that CM from antiarrhythmic-treated CAFs on 










































































































































































































































































































Figure 4. 19. Antiarrhythmics impair CAF-mediated EMT in PCa cells. (Upper panel) 
Expression levels of the epithelial markers (CDH1 and CTNNB1), and mesenchymal 
markers (VIMENTIN and SNAI)  assessed by qRT-PCR in DU145 and PC-3 cells exposed to 
CM of HPF or CM of CAF exposed on not to antiarrhythmics. Data are reported as relative 
expression with respect to untreated cells and are representative of three independent 
experiments . (Middle panel) Western blotting analysis showing E-cadherin, β-catenin, 
Vimentin and Snail protein amount in DU145 cells exposed to CM of HPF or CM of CAF 
exposed on not to antiarrhythmics, normalized to β-tubulin. (Lower panel) The bar plot 
reports quantification of western blots. Densitometry data are reported as raw normalized 
values (arbitrary units) towards the loading control (β-tubulin). The level of significance was 
represented as *p<0.05, **p<0.01, Student’s test. 
 
 
4.3.4. Antiarrhythmics affect CAF pro-migratory boost on DU145 cells  
Considering the relevance of migratory capability in the dissemination process, and 















































































































, we evaluated whether antiarrhythmics treatment could revert CAF-
promoted migratory boost on DU145 cells. For this sub-set of experiments, we 
sought to focus on those antiarrhythmics that showed, in our hands, a greater 
capability to impact on ECM remodelling process mediated by CAFs (Figure 4.11), 
and a prominent reduction of PCa cell growth and EMT modulation in CM co-
culture experiments (Figure 4.16 and 4.19). For this purpose, the capability of DU14 
to migrate and recover a wound were tested using a common scratch assay. 
Specifically, DU145 cells were seeded, and the monolayer of cells were wounded by 
manual scratching with a pipet tip, washed with PBS, photographed (0 h point) and 
media were replaced with CM of HPFs or CM of CAFs treated or not with nifedipine 
or flecainide. Images of cell movement were captured at 24 hours. As indicated in 
the representative photomicrographs and bar graph, DU145 cells exposed to CM of 
CAFs displayed a high capacity to close the wound. Conversely, the CM of 
antiarrhythmic treated CAFs significantly reduced DU145 cell effectiveness to close 
the wound, showing a wound-healing ratio that partially recapitulated CM of HPFs 
effect, which is known to acts as a tumour suppressor. These findings suggest that 
nifedipine and flecainide decreased CAF mediated pro-migratory boost on DU145 































































Figure 4. 20. CM of antiarrhythmics-treated CAFs impairs DU145 cell 
migratory capability. (Upper panel) Representative phase contrast microscopy 
images showing migration rate of DU145 cells exposed to CM of HPF, or CM 
of CAFs treated or not with nifedipine or flecainide (scale 100 µm). The dotted 
lines define the areas lacking cells. (Lower panel) Bar plots showing the wound-
healing rate of DU145 cells upon the indicated treatments, as from scratch 
assay. Data are reported as wound healing ratio at 24 h compared to 0 h and are 
representative of three independent experiments. The level of significance was 
represented as * p<0.05, ** p<0.01, Student’s t-test. 
  
 
4.3.5. Antiarrhythmics reduced MMP secretion by CAFs  
Considering our data showing that upon antiarrhythmic treatment CAFs lose their 
migratory and ECM remodelling capability and display a reduced pro-tumoural 
potential, we attempted to investigate soluble factors involved in these aspects. Since 
MMP up-regulation is well established to be associated with an increase in cell 
motility and extracellular matrix remodelling in PCa setting 
121
, we assessed MMP 































expression levels in CAFs exposed to antiarrhythmics, and HPFs as comparison. 
Specifically, we sought to focus on MMP-2, which is reported to be largely released 
by CAFs and also associated with the presence of bone metastasis in PCa patients. 
Western blotting analysis confirmed that CAFs were able to release high levels of 
MMP-2 in the CM. Controversially, CAFs treated with nifedipine or flecainide, 
showed a substantial reduction of MMP-2 production, both for the pro-MMP2 and 
the relative activated form, thus recapitulating HPF status. Surprisingly, as shown in 
figure 4.19, the amount of MMP-2 was not decreased in cell lysate with respect to 
the corresponding CM sample, suggesting that antiarrhythmics could specifically 


















Figure 4. 21. Antiarrhythmics reduced MMP-2 release in 
the CM. (Upper panel) Western blotting analysis showing 
pro-MMP-2 and active-MMP-2 protein levels in CM and cell 
lysate of CAFs treated or not with nifedipine or flecainide, 
and HPFs. (Low panel) Quantification of MMP-2 western 
blotting analysis showing the CM/cells ratio. 
 
 
4.3.6. Antiarrhythmic-treated CAFs impaired tumour growth of PC xenografts 
To further confirm the obtained results showing that antiarrhythmics treatment can 
modulate CAF activated phenotype and reduce their pro-tumoural boosts, we tested 
the antiarrhythmic-mediated effects on CAF-PCa interplay by performing in vivo 
experiments.  
First of all, we investigated the possibility of performing in vivo experiments by on 
the immortalized stromal cell line WPMY-1, which would be more easy to expand in 
culture as compared to the primary fibroblasts used in the previous part of the 



















project. Following this strategy, WPMY-1 cells were exposed to CM of DU145 cells, 
in order to induce their activation in vitro, then we tested the activated state through 
the evaluation of specific fibroblast activation markers and cation channel expression 
levels. As shown in figure 4.22, WPMY-1 cells exposed to CM of DU145 cells 
displayed an activated phenotype indicated by the up-modulation of α-SMA, 
COL1A1 and FAP, and the concomitant up-modulation of ion channel CACNA1H, 













































































Figure 4. 22. Evaluation of WPMY-1 activated state. (Panel A - left and upper right) 
qRT-PCR and western blotting analysis showing fibroblast activation marker expression 
levels (α-SMA, COL1A1 and FAP) in WPMY-1 cells exposed to CM of DU145 cells. 
(Panel B-left and upper right) qRT-PCR and western blotting analysis showing the 
expression of ion channels CACNA1H, CACNB1, SCN2A and SCN1B in WPMY-1 
cells exposed to CM of DU145 cells. (Lower panel right A and B) Western blots 
quantifications are reported as bar blots and densitometry data as raw normalized values 
(arbitrary units) towards the loading control (β-tubulin). qRT-PCR data are reported as 
relative expression with respect to untreated WPMY-1 cells and are representative of 
three independent experiments. The level of significance was represented as * p<0.05, 
** p<0.01, Student’s t-test. 
 
To assess whether antiarrhythmic treatment was able impair to WPMY-1 activated 
state and reduce their tumoural promoting effects, as observed in fibroblast primary 
cultures, we exposed activated-WPMY-1 cells (aWPMY-1) to nifedipine and 
flecainide. As shown in figure 4.23, antiarrhythmics treatment was able to partially 
reduce WPMY-1 activation, as indicated by the reduction of α-SMA, COL1A1 and 
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Figure 4. 23. Antiarrhythmics effects on WPMY-1 activated state. (Upper and lower left 
panels) qRT-PCR and western blotting analysis showing fibroblast activation marker 
expression levels (α-SMA, COL1A1 and FAP) in aWPMY-1 cells exposed to nifedipine or 
flecainide, compared to WPMY-1 cells. (Lower right panel) Western blots quantifications 
are reported as bar blots and densitometry data as raw normalized values (arbitrary units) 




















































































































with respect to aWPMY-1 cells and are representative of three independent experiments. The 
level of significance was represented as * p<0.05, ** p<0.01, Student’s t-test. 
 
Finally, we evaluated antiarrhythmics impact on aWPMY-1 and PCa interplay. In 
this regard, as performed above for fibroblast primary cultures, we performed an 
indirect co-culture experiment. Specifically, DU145 cells were exposed to CM of 
parental WPMY-1 or aWPMY-1 cells treated or not with nifedipine or flecainide and 
cultured until 72 hours.  The treatment of aWPMY-1 cells with antiarrhythmics 
reduced their capability to sustain DU145 cells proliferation, as indicated by the 
significant reduction of cell growth rate as compared to that of cells stimulated with 
CM from untreated aWPMY-1, recapitulating the trend observed when PCa cells 







Figure 4. 24. Antiarrhythmics impair CAF capability to promote DU145 cell growth. 
DU145 cell growth evaluation cultured with CM of parental WPMY-1 or aWPMY-1 cells 
treated or not with nifedipine or flecainide at different time points (24, 48, 72 hours). Data 
reported are representative of three independent experiments. The level of significance 
was represented as * p<0.05, ** p<0.01, *** p<0.001 Student’s t test. 
 
Once verified the suitability of the fibroblast cell model for in vivo experiments, 
DU145 cells were injected in to the right flanks of SCID mice, and let to grow thus 
leading to the onset of subcutaneous PCa tumours. When the tumours reached a 
volume ≈ 150 mm
3
, CM of parental WPMY-1 or of aWPMY-1 cells exposed or not 
to nifedipine or flecainide was intratumourally injected into PCa xenografts for 5 
consecutive days for a total of 2 weeks. Tumour volumes were determined every 4 
days with a Vernier caliper. In consonance with what observed before, the tumours 
exposed to CM of aWPMY-1 cells treated with antiarrhythmics displayed a 
significant tumour growth delay, resembling the trend observed for tumours treated 












































with CM of parental WPMY-1 cells, which is recognized as tumour suppressive 
stimulus (Figure 4.25).   
 
 
Figure 4.25. Antiarrhythmics significantly impair the capability of activated 
fibroblasts to sustain tumour growth in vivo. DU145 cells were subcutaneously 
injected into the right flanks of SCID mice. When tumours reached the volume of 150 
mm
3
, mice were randomly separated in five groups (six mice/group) and were 
intratumourally treated 5 days for 2 weeks with CM of parental WPMY-1 or of aWPMY-
1 cells treated or not with nifedipine or flecainide. The level of significance was 
represented as * p<0.05, ** p<0.01, *** p<0.001 Student’s t test with respect to DU145.  
 
In addition, in order to investigate the impact on tumour growth upon 
intratumourally treatment with CM of aWPMY-1 exposed or not to 
antiarrhythmics, immunohistochemical analysis of Ki‐67 in tumour xenograft 
tissues has been performed. Results indicated a significant decrease of Ki-67 
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nifedipine (6.0% ± 1.1%) or flecainide (7.2% ± 2.0%) compared to untreated 
group (21.3% ± 4.2%), resembling the trend observed for tumours treated with CM 
of parental WPMY-1 cells (6.3 ± 1.4%). No significant differences were 




Figure 4.26. Proliferation rate in PCa xenografts. (Upper panel) 
Representative images of KI-67 immunohistochemical staining (stained in 
brown) in PCa xenografts intratumouraly treated with CM of parental WPMY-
1, aWPMY-1 exposed or not to nifedipine of flecainide. (Lower panel) 
































































each samples. The level of significance are represented as * p<0.05, Student’s 
t test with respect to untreated group.  
 
 
Moreover, western blotting and qRT-PCR analysis revealed that intratumoural 
administration of CM of aWPMY-1 cells exposed to antiarrhythmics was able 
to affect PCa xenograft plasticity, as indicated by E-cadherin up-modulation. 
As shown in figure 4.27, E-cadherin levels were slightly decreased in 
xenografts treated with CM of aWPMY-1 cells. In contrast, CM of aWPMY-1 
cells exposed to nifedipine or flecainide was no longer able to decrease E-
cadherin, rather it increased its levels, similarly to what observed in xenografts 








Figure 4.27. Antiarrhythmics revert CAF-mediated EMT in PCa xenografts. (Upper 
panel) Expression levels of the epithelial marker CDH1 assessed by qRT-PCR in PCa 
tumours treated with CM of parental WPMY-1 or of aWPMY-1 cells exposed or not to 
nifedipine or flecainide. Data are reported as relative expression with respect to untreated 
tumours. (Lower panel left) western blotting analysis showing E-cadherin protein amount in 
PCa tumours treated with CM of parental WPMY-1 or of aWPMY-1 cells exposed on not to 
nifedipine or flecainide, normalized to β-tubulin. (Lower panel right) Western blots 




































































































(arbitrary units) towards the loading control (β-tubulin). The level of significance was 






5. RESULTS II. Identification of potential stromal biomarkers for risk 
assessment in Active Surveillance patients  
 
In PCa setting, active surveillance (AS) has evolved as an alternative to radical 
treatment for patients with very low risk, potentially indolent tumours. AS patients 
are strictly monitored and curative treatments are avoided or deferred until evidence 
of more aggressive PCa 
122
. Eligible AS patients have clinical stage T1/T2 PCa, PSA 
levels in the blood ≤10 ng/ml, PSA density <0.2 ng/ml per millilitre, one or two 
positive biopsy cores, and Gleason pattern score (GPS) ≤ 6. 
Patients enrolled in AS are monitored by measuring PSA levels every 3–6 months, 
and follow-up biopsies are scheduled after 1, 4, and 7 years of AS inclusion 
122
. 
Despite this stringent protocol, the aforementioned selection criteria are suboptimal 
and about 1/4 of patients discontinue AS because of PCa reclassification/progression, 
mainly for up-grading (change from GPS ≤ 6 to GPS > 6), or for the detection of 
more than two positive cores at the time of the first repeated biopsy 
123
. This frame 
highlights the urgent need of novel biomarkers for an unequivocal classification of 
indolent disease, thus allowing the early identification of occult high-risk PCa 
tumours during biopsy procedures. In this regard, the PCa stroma, characterized by 
an increased desmoplastic and inflammatory environment, could potentially improve 
AS patients’ classification.  
Considering our recently observation on the crucial role of reactive stroma in PCa 
setting 
89
, we hypothesized that the existence of peculiar reactive stroma in GPS=6 
core biopsies (or even in negative biopsies) could be indicative of an adjacent 
undetected high-grade PCa tumour, and therefore potentially reduce disease 





investigating the potential of stromal biomarkers for high-grade PCa detection was 
supported by literature evidence reporting that the percentage of myofibroblasts is 
increased in the stroma of poorly differentiated GPS > 6 compared to GPS ≤ 6 
tumours 
70
. Moreover, the expression of α-SMA stromal marker in radical 
prostatectomy specimens has been reported to correlate with PCa grade 
74
. 
Considering this premise, the aim of this translational part of the project is to define 
the potential of selected stromal genes found to be consistently up-regulated PCa 
activated stroma as novel stromal tissue and/or circulating biomarkers for risk 











5.1. Identification of potential stromal biomarkers in PCa sample. 
 
Despite intensive efforts in the characterization of tumour-stroma interplay have led to 
the identification of factors that contribute to sustain this crosstalk, further attempts are 
required to understand the crucial molecular pathways that govern tumour stroma 
activation. In this regard, defining a stromal gene signature relevant for cancer 
progression could be a successful strategy to identify novel prognostic biomarkers for 
PCa. Recently, we have performed a gene expression profiling analysis comparing 
prostate CAFs and normal fibroblasts stimulated with IL-6 or TGF-β, to examine the 
molecular signatures involved in fibroblast activation. This analysis highlighted that 
PCa reactive stroma was influenced by IL-6 and TGF-β signalling, even if with 
different extent and most likely with different roles 
89
. Specifically, GSEA highlighted 
that genes related to ECM modulators were positively enriched in CAFs, IL-6- or TGF-
β-activated fibroblasts. 
Whit the aim of identifying gene functionally involved in fibroblast activation and 
potentially suitable as stromal biomarkers for AS patients, we selected a set of genes 
related to reactive stroma and up-modulated in CAFs or HPFs activated in vitro with 
IL-6 or TFG-β. Combining these criteria, we identified POSTN, COL10A1, COL11A1, 
SPARC and COMP, genes related to extracellular matrix remodelling and 
tumourigenesis process 
124
, as significantly up-modulated in at least one of our 
activated fibroblast sets (Figure 5.2). Among these genes, we focused on POSTN. As 
shown in figure 5.2, POSTN was found to be significantly up-modulated in all 
activated fibroblasts (CAFs, normal fibroblasts activated in vitro with IL-6 and TGF-β) 
with respect to HPFs. POSTN gene codes for the protein periostin, which is a secreted 










Figure 5. 2. Stromal related genes showing differential expression 
in activated fibroblasts compared to HPFs. List of extracellular 
matrix related genes found to be associated with fibroblast activation 
phenotype in CAFs and HPFs activated in vitro with IL-6 or TGF-β, 
compared to HPFs. 
 
 
5.1.1. POSTN expression in PCa setting 
The reason why we selected POSTN (i.e. periostin) is that this gene was found to be 
up-regulated in prostate CAFs and HPFs activated in vitro with IL-6 and TFG- β and 
that, moreover POSTN expression was found to be associated with is tumourigenesis 
processes 
125
. These findings indicate that POTSN could be a valid candidate biomarker 
for improve AS patient selection. In support to this, high expression levels of POSTN 
mRNA were found to significantly correlate with a higher probability to experience 
biochemical recurrence (BCR), which is the rise of PSA blood levels upon radical 
CAFs HPFs-IL6 HPFs-TGF-β 
logFC p-value logFC p-value logFC p-value 
POSTN 1.226143 0.00763 1.303061 0.00126 1.194951 0.0002 
COL10A1 -0.01245 0.91915 0.06279 0.66751 0.500536 0.08124 
COL11A1 1.718046 0.07488 1.896297 0.04705 0.710533 0.01056 
SPARC -0.35811 0.23563 -0.25752 0.478502 0.595899 0.00128 





























treatment (e.g. radical prostatectomy or radiotherapy), in ≈ 100 clinical PCa samples 
(Taylor dataset GSE21032) 
126




Figure 5. 3. POSTN mRNA expression correlates with BCR in clinical PCa 
samples from Taylor data set. Hazard Ratio (HR) indicating a significant 
association of POSTN mRNA expression in ≈ 100 clinical PCa samples with BCR.  
 
 
Moreover, to both check the suitability and the reliability of our hypothesis, we 
validated our gene expression results in an independent panel of three CAFs isolated 
from tumoural areas of PCa specimens with respect to the HPFs. qRT-PCR analysis 
showed a considerable up-modulation of POSTN mRNA in the independent panel of 
CAFs, thus confirming our preliminary observation (Figure 5.4).  
 
BCR  
HR CI. low CI. up p-value 






Figure 5. 4. POSTN is overexpressed in CAFs. Expression levels of 
POSTN assessed by qRT-PCR in three different CAFs isolated from 
tumoural area of radical prostatectomy samples. Data are reported as 
relative expression with respect to matched-HPFs. The level of 
significance was represented as p*<0.00, Student’s t-test. 
 
 
5.1.2. Evaluation of periostin (POSTN) protein expression in radical prostatectomy 
samples  
Our initial hypothesis was to test the presence of a specific reactive stromal signature in 
GPS=6 core biopsies (or even in negative biopsies) collected at the time of PCa 
diagnosis, and correlates such unique feature with disease reclassification during AS 
monitoring. Unfortunately, the use of diagnostic core biopsies raises several issues 
related to the very small sample size (technical issue) and the actual possibility to 
completely deplete such small samples (legal issue) during investigation analyses. In 
this scenario, we sought to take advantage from a large series of Formalin Fixed and 










































this valuable cohort i) to set up the appropriate conditions to detect periostin (e.g. 
POSTN) protein expression in the stroma infiltrating tumour foci, by using 
immunohistochemistry (IHC) techniques, and ii) to preliminary assess the clinical 
relevance of periostin expression, in terms of association with clinico pathological 
features and patient outcome. The case series consisting of FFPE tissue sections from 
116 PCa patients subjected to radical prostatectomy with a minimum follow-up of 5 
years, including 31 patients that experienced biochemical failure and 85 that had no 
evidence of recurrence. To simulate the AS setting, specimens characterized by GS ≤ 6 
cancers were included. At first, the samples were evaluated by an expert uro-
pathologist to identify proper areas to be macro-dissected for IHC. Under close 
supervision of the uro-pathologist, we analysed IHC periostin staining to provide a 
semi quantitative score to be used to assess correlation between protein expression in 
the stroma and clinico pathological characteristics of the tumour and/or patient 
outcome. We designed a semi quantitative score, by setting up an arbitrary scale 
ranging from 0 to 3, where 0 represents no periostin stromal staining and 4 the highest 
stromal staining observed in the tissue sections. Once defined the score, sections with 
stromal tumoural score from 0 to 1 were classified as “low”, and sections with score of 
2 or 3 were classified as “high”. As shown in figure 5.5, we found that periostin (in red) 
is manly expressed in the stroma area (labelled with S) surrounding tumoural foci 
(labelled with T). Moreover, results from 116 FFPE prostatectomy samples showed a 
significant correlation between stromal periostin score and tumour grade. Specifically, 
we observed that higher expression of periostin was found in the stroma of GS > 6 
tumours. In fact, the 81% of the tumours classified as GS > 6 displayed a high periostin 
score, and only 19% were classified as low periostin score. Conversely, low score was 










Figure 5.5. Periostin stromal staining correlates with tumour grade 
in PCa specimens. (Upper panel) Representative image of a FFPE 
section of high grade PCa stained for H&E and periostin protein (red), 
showing an intense staining in the stroma (S) surrounding tumour foci 
(T). (Low panels) Bar plot and table comparing periostin stromal score 
(high or low) and GPS in the PCa cohort. The level of significance was 
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GPS ≤ 6 38 33 (87%) 5 (13%) 
GPS > 6  78 15 (19%) 63 (81%) 


























Moreover, we highlighted an interesting correlation between periostin score and a 
specific subgroup of GS 7 tumours. Tumour GS is defined by adding the two most 
common Gleason patterns observed in PCa specimens. The GS 7 tumours are mainly 
composed of the patterns 3 and 4 (3+4 or 4+3). Patients with GS 7 demonstrate a wide 
range in clinical outcomes, suggesting the urgent need of novel outcome predictors in 
this setting. Recently, uro-pathologist observed that a subgroup of patients 
characterised by cribriform morphology tumour growth in pattern 4 displayed a poor 
prognosis, indicating that this specific histological pattern requires an unequivocal 
annotation and identification during diagnosis due to the relevant impact on patient’s 
outcome 
127
 .  
In this regard, we observed a significant association of periostin score and the presence 
of cribriform morphology in pattern 4 tumours of our cohort of 74 FFPE prostatectomy 
samples displaying GS 7. As shown in figure 5.6, we found that 100% of tumours with 
cribriform morphology in the pattern 4 displayed a high periostin score. Conversely, 
despite the high periostin score was anyway found to be relevant for GS 7 tumours, the 
76% of the tumours characterised by non-cribriform morphology was classified as high 
score and the 14% as low. These pieces of evidence suggest a possible correlation 







Figure 5.6. Periostin score correlates with cribriform 
growth in the sub-group of GS 7 tumours. Bar plot and table 
comparing periostin stromal score (high or low) and cribriform 
pattern in a sub-group of 74 GS 7 tumours. The level of 
significance was represented in accord to chi-squared test. 
 
 
5.1.3. Evaluation of periostin as a potential prognostic tissue biomarker for risk 
assessment in PCa setting 
Once assessed the correlation between stromal periostin staining and tumour grade in 
the cohort of prostatectomy specimens, we investigated the prognostic value of 
periostin score. In PCa, the crucial event that is indicative of a possible failure of 
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biochemical recurrence (BCR) that is rising of PSA levels in the blood after radical 
treatments. In order to investigate the prognostic potential of periostin, we initially 
performed a univariate analysis considering several clinico-pathological characteristics, 
including: surgical margin, extraprostatic extension (EPE), seminal vesicle invasion, 
perineural invasion, GS and periostin score. As shown in figure 5.7, the univariate 
analysis indicated that periostin score (HR=6.98; IC 95%: 2.11, 22.95), surgical margin 
(HR=3.83; IC 95%: 1.77, 8.29), EPE (HR=3.83; IC 95%: 1.77, 8.29), seminal vesicle 
invasion (HR=3.57;IC 95%: 1.51, 8.47), perineural invasion (HR=2.25; IC 95%: 1.01, 
5.02) and GS (HR=2.62; IC 95%: 1.00, 6.86) were all related to BCR, with periostin 
score having the highest HR. Moreover, 7-year BCR probability stratified for periostin 
score indicated that high periostin score displayed a moderate capability to predict 
biochemical failure event in PCa patients. 
 
  
Figure 5. 7. Univariate Cox model and Kaplan-Meier analysis of biochemical-relapse free 
survival in PCa patients according to periostin score. (Left panel) Table reports Hazard 
Ratio (HR) value obtained considering several clinico-pathological variables (surgical margin, 
EPE extraprostatic extension, seminal vescicle invasion, GS= Gleason score) and 
Patient Cohort: 116 
event: 31 biochemical failure
median FU: 84 months (IQR: 65-104)
low
high
Variable  HR  95%CI  
Surgical margin  
> 1 vs 0 3.83 1.77 8.29 
Periostin score  
high vs low 6.96  2.11  22.95  
EPE  
yes vs no 3.38  1.54  7.39  
Seminal vesicle invasion 
1 vs 0 3.57  1.51  8.47  
Perineural invasion 
yes vs no 2.25  1.01  5.02  
GS 


































periostin staining. (Right panel) Periostin stromal score with respect to biochemical recurrence 






5.2. Identification of potential stromal circulating biomarkers in PCa sample 
 
Considering the abovementioned critical aspects related to the assessment of stromal 
biomarkers in core biopsies obtained from AS patients, we sought to investigate their 
prognostic potential as circulating biomarkers. Our findings indicating a positive 
correlation between periostin score and aggressive disease (GS > 6) (Figure 5.5) and a 
moderate association of periostin score with disease outcome (Figure 5.7) prompted us 
to investigate the potential of periostin as a circulating biomarker for disease 
reclassification in AS patients. With the same aim, we decided to extend our 
explorative evaluation adding a panel of four ECM proteins that we previously 
described as up-modulated in CAFs or normal fibroblasts activated in vitro with IL-6 or 
TGF-β, compared to normal fibroblasts (Figure 5.1): col11a1, col10a1, sparc and comp. 
 
5.2.1. Evaluation of ECM signature in CM of CAFs and PCa plasma patients 
With the aim of investigating the potential value of stromal circulating biomarkers, we 
initially performed an explorative evaluation of ECM protein amounts in the CM of 
patient-derived CAFs and HPFs, in order to assess the reliability of our hypothesis. 
Western blotting analysis indicated that periostin, col11a, col10a, sparc and comp were 
detectable in the CM of fibroblasts and, in agreement with gene expression data, their 
expression levels were found to be increased in CM of CAFs with respect to HPFs 







Figure 5.8. ECM proteins were increased in CM of CAFs. Western 
blotting showing reactive ECM-related protein amount (periostin, col11a, 
col10a, comp and sparc) in CM from CAFs with respect to that from HPFs. 
The bar plot reports quantification of western blot. Densitometry data are 
reported as raw normalized values (arbitrary units).  
 
 
Moreover, we assessed the expression levels of our ECM signature in plasma samples 
collected at inclusion in AS (baseline) of two patients who dropped out of AS protocol 
due to disease reclassification (upgrading), two patients who remained in AS for more 
than 5 years (indolent), and for comparison we analysed the levels of ECM proteins in 
the plasma obtained at diagnosis (baseline) of two patients with a clinically significant 
disease subjected to radical treatment. A shown in figure 5.9, we found a high amount 
of perostin, col10a1, comp and sparc in the plasma of patients with clinically relevant 
tumours and moderated levels in that of AS patients belonging to the upgrading group. 






















Figure 5.9. ECM proteins were increased in baseline plasma samples of 
upgrading AS patients and clinically significant PCa patients. Western blotting 
showing periostin, col10a, comp and sparc amounts in plasma samples obtained at 
the diagnosis in indolent or upgrading AS patients and patients with clinically 
significant disease.  
 
 
5.2.2. Evaluation of ECM protein levels in plasma sample from AS patients  
In order to identify circulating biomarkers able to discriminate between PCa patients 
with indolent tumour, truly eligible for AS, and patients who discontinued AS due to 
upgrading at the fist re-biopsy, we tested the potential of our ECM signature on plasma 
samples collected at the inclusion in AS protocols. At first, in order assess the 
reliability of our stating point, we evaluated periostin, col11a1, col10a1, sparc and 
comp baseline plasma levels in an explorative cohort of 40 AS patients, including 20 
patients who discontinued AS due to upgrading at the fist re-biopsy (1 year) and 20 
patients still in AS for at least 5 years. ELISA-based assessment analysis indicted that 
only sparc displayed a moderate differential expression between the two groups of 
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Figure 5. 10. ECM signature plasma levels in an explorative cohort of AS patients. 
Quantification of periostin, coll11a1, coll10a1, comp and sparc plasma levels using 
ELISA assay in 40 AS patients, of which 20 from the indolent (IND) and 20 from the 
upgrading (UP) group. Data are reported as absorbance (optical density). Wilcoxon test 
was performed and p<0.05 was considered significant. 
 
 
5.2.3. Evaluation of a logistic model for AS risk assessment based on circulating 
periostin and sparc 
Considering our findings that indicated a moderate association of sparc with disease 
reclassification, and with the aim of improving the relevance of our circulating 
signature, we sought to define a prognostic model combining sparc and periostin 
predictive values. At first, logistic models were developed by considering circulating 
sparc levels as a continuous or as a categorical variable (index score). The logistic 
model with sparc modulated as a continuous variable revealed to have an area under the 




































levels of circulating sparc had a moderate capability to discriminate between the 
indolent and upgrading AS patients (Figure 5.12, left panel). More interestingly, when 
sparc was combined with periostin, we observed an increase of the AUC value from 
0.695 to 0.725 (AUC: 0.725; 0.555, 0.867), suggesting that the combination slightly 
improved the moderate predictive power of the model (Figure 5.11, right panel). As 
shown in table 5.13 (low panel), sparc also showed moderate association with the 
probability of upgrading occurrence (Odds Ratio (OR) 4.14; IC 95%: 1.04;-16.51). 
When combined with periostin, the model displayed a higher probability to predict 








Figure 5. 11. Receiver Operating Characteristics (ROC) curves and Odds 
Ratio (OR) value for potential predictors in AS patients. (Upper panel) Areas 
under the ROC curves (AUC) and relative 95% confidence interval measurement 
of sparc or of saprc/periostin combination. The area AUC represents the accuracy 
of the individual and combined potential biomarkers for distinguishing upgrading 
patients in AS protocols. (Lower panel) OR values were defined by using of sparc 
(model 1) or sparc and periostin circulating levels (model 2) as continuous variable 
to estimate the risk to experience upgrading event during AS. Abbreviations: 
AUC= Area Under the ROC Curve, OR = Odds Ratio, CI = 95% Confidence 
Interval, p= p-value, C = Harrell's C discrimination index. 
 
To further investigate the potential of sparc and periostin as predictors of upgrading 
event in AS patients, we developed a logistic model based on index score. Specifically, 
the index was defined by combining arbitrary scores assigned to specific sparc and 
periostin quantification levels. Following this strategy, we confirmed that high 
LOGISTIC MODELS WITH CONTINUOUS VARIABLE
OR [CI] p C
Model 1
SPARC 4.14 [1.04; 16.51] 0.103 0.696
Model 2
SPARC 4.89 [1.14; 20.96] 0.07 0.722





expression levels of sparc was per se indicative of an increased probability of 
experiencing upgrading (OR 4.33 IC95%: 1.15-16.32; C 0.675) and that, by adding 
periostin to the model, such probability was improved (OR 4.33; IC95%: 1.15-16.32; C 
0.702). Overall, these findings indicated that both logistic models were improved by the 
addition of periostin. 
 
Figure 5. 12. . Logistic model with index score for risk 
assessment in AS patients. OR values were defined by 
combining sparc and periostin circulating levels as categorical 
variables to estimate the risk to experience upgrading event during 
AS. Abbreviations: AUC= Area Under the ROC Curve, OR = 
Odds Ratio, CI = 95% Confidence Interval, p= p-value, C = 
Harrell's C discrimination index. 
 
 
5.2.4. Evaluation of periostin and sparc as potential predictors in an extended cohort 
of AS patients  
To further support these results, we investigated the ability of circulating sparc and 
periostin to predict upgrading in an extended cohort of AS patients, including plasma 
samples collected at inclusion in AS protocol form a total of 60 patients, of whom 20 
discontinued AS due to upgrading at the re-biopsy, and 40 still in AS for at least 5 
years. As described for the explorative experiments, we assessed circulating sparc and 
OR [CI] p C
SPARC 4.33 [1.15; 16,32] 0.030 0.675
SPARC and 
PERIOSTIN
20.54 [1.59; 265.02] 0.021 0.702





periostin protein levels in baseline plasma samples by using ELISA assays. In 
agreement with what we observed in our explorative experiments, the results derived 
from the combination of the two series (explorative and extended cohort) consisting of 
100 patients (40 up-grading and 60 indolent) highlighted that the ability of sparc to 
discriminate between the two groups of patients was better than that of periostin, 
although the data did not reach statistical significance (Figure 5.13).  
 
Figure 5. 13. Sparc and periostin plasma levels evaluated in a cohort of 100 AS patients. 
Quantification of sparc and periostin plasma levels using ELISA assays in 100 AS patients, 60 
from the upgrading group (UP) and 40 from the indolent group (IND). Data are reported as 




In contrast to our previous observation, the logistic models obtained by modulating 
sparc as a continuous variable indicated that the AUC of sparc reached a value of about 
0.598 (figure 5.14, left panel), lower than our previous model (figure 5.12). 
Unfortunately, our results indicated that when periostin was added to the logistic 
























































p = 0.4286  p = 0.1175 





discriminate between patients really suitable for undergoing an AS protocol and 
patients who experience upgrading event at the first re-biopsy (AUC: 0.616; IC 95% 
0.505-0.726) (Figure 5.14).  
 
 
Figure 5. 14. Receiver Operating Characteristics (ROC) curves and Odds Ratio (OR) 
value for potential predictors in AS patients. (Upper panel) AUC and relative 95% 
confidence interval value of sparc and sparc combined with periostin. The area AUC 
represents the accuracy of the individual and combined potential biomarkers for 
distinguishing upgrading patients in AS protocols. (Lower panel) OR values were assessed by 
using of sparc or sparc and periostin circulating levels as continuous variable to estimate 
upgrading event during AS.  Abbreviations: AUC= Area Under the ROC Curve, OR = Odds 
Ratio, CI = 95% Confidence Interval, p= p-value,C = Harrell's C discrimination index. 
LOGISTIC MODELS WITH CONTINUOUS VARIABLE 
	 OR [ CI ] 	 p	 C	
Model 1  
SPARC 2.41 [1.04;5.58]    0.115 0.598  
Model 2  




SPARC 1.60 [0.88;2.92]   0.124 0.617 
PERIOSTIN 0.65 [0.37;1.14]  0.134 
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AUC = 0.5992 [ 0.4873 ; 0.7083 ]
Sparc 
LOGISTIC MODELS WITH CONTINUOUS VARIABLE
OR [CI] p C
Model 1
SPARC 2.41 [1.04; 5.58] 0.115 0.598
Model 2
PERIOSTIN 0.78 [0.36; 1.71] 0.417 0.564
Model 3
SPARC 1.60 [0.88; 2.92] 0.124 0.617






5.2.5. Circulating periostin levels are elevated in patients with clinically significant 
PCa 
Considering the limitations of studying novel prognostic biomarkers in AS cohorts, 
which include patients characterised by low-grade tumoural foci (GS ≤ 6) and low 
tumoural burden (n<2 of positive cores biopsy at the diagnosis), we sought to assess the 
prognostic potential of circulating periostin in patients with clinically relevant organ-
confined PCa, who are subjected to radical therapies. In this setting, we assessed 
exclusively the plasma levels of periostin due to our findings highlighting the 
correlation between periostin score and PCa tumour grade. Specifically, we evaluated 
periostin levels in the plasma collected at the diagnosis (baseline) from 21 patients with 
GS >6 PCa tumours treated with radical radiotherapy, by using ELISA assays. 
Interestingly, in this cohort of PCa patients, we found significantly enhanced 
circulating periostin levels with respect to AS patients. This piece of evidence further 
confirmed our previous observations, suggesting that elevated periostin plasma levels 







Figure 5. 15. Periostin plasma levels evaluated in PCa patients. Quantification of 
periostin plasma levels using ELISA assays in 100 AS patients (60 upgrading group 
(UP), 40 indolent group (IND)) and 21 clinically relevant PCa patients (GS>6). Data 
are reported as plasma concentration (ng/ml). The level of significance was reported as 




















































































































6.1. Drug repositioning approaches to counteract the activated phenotype of 
CAFs  
Tumours display a complex and heterogeneous microenvironment consisting of stromal 
cells, structural components, and immune infiltrating cells 
128
. In the last decade, 
several studies highlighted the important role of tumour microenvironment in 
promoting cancer progression and dissemination 
129
. Among the cellular populations 
within the tumour microenvironment, fibroblasts are the most represented cells of the 
reactive stroma. In normal tissues, fibroblasts are quiescent and play suppressive 
functions, covering the regulation and the repression of abnormal epithelial cell growth 
130
. However, in the tumour microenvironment cancer-associated fibroblasts (CAFs) 
become activated, thus changing their cell functions and structure. CAF functions range 
from promoting tumour cell proliferation, migration and invasion, to modulating 
tumour immunosuppressive environment and pro-inflammatory factors secretion 
131
. In 
PCa, it has been reported that the reactive stroma fosters tumour progression and 
affects response to therapies. However, the mechanisms that underlie such processes 
are not clear and further investigations are needed 
81132
. In this regard, defining relevant 
reactive stromal gene signatures for PCa progression could help understand tumour-
stroma crosstalk and promote the development of novel therapeutic strategies aimed at 
targeting the stroma rather than tumour cells. 
For this reason, we have recently performed a gene expression profiling analysis 





stimulated with interleukin-6 (IL-6) or transforming growth factor-β (TGF-β), in order 
to define the molecular signatures involved in fibroblast activation 
89
. Results from this 
study showed that prostate-derived CAF transcriptome strictly resembles that of normal 
fibroblasts stimulated in vitro with IL-6, showing for the first time that IL-6 is able per 
se to induce most of the transcriptional changes characteristic of patient-derived CAFs. 
Interestingly, gene sets related to glycolysis/gluconeogenesis and muscle contraction, 
including the so-called “cardiomyopathy” gene set and “voltage-gated cation channel 
activity”, were found positively enriched in all types of activated fibroblast profiled, 
suggesting a crucial role for such pathways in stromal phenoconversion 
89
. Hence, an 
intriguing scenario emerged concerning a possible similarity between prostate CAFs 
and myocardiocytes.  
Based on these findings, we were encouraged to pursue the identification of stromal 
gene signature functionally involved in fibroblast activation, in order to investigate 
therapeutic approaches aimed at targeting CAFs in the PCa microenvironment. Among 
the genes that we found differently expressed and up-modulated in CAFs, we focused 
on “voltage-gated channel activity” gene set, which includes genes coding for cation 
channel proteins involved into the regulation of cation flux across cell membranes 
89
.  
Currently, scanty information is available on cation channels’ role in prostate CAFs. In 
this regard, Vancauwenberghe and collaborators reported that stromal TRPA1-calcium 
channel was able to reduce resveratrol-induced apoptosis in PCa cells 
133
. However, the 
role of cation channels has been widely studied in physiological and pathological 
processes, including carcinogenesis. Noteworthy, Prevarskaya and colleagues 
categorised the carcinogenesis process as a special type of “channelopathy”, due to the 





cancer hallmarks, including aberrant cellular proliferation and differentiation, 
uncontrolled apoptosis, and increased cellular motility 
134
.  
Encouraged by the relevance of cation channel involvement in physiological processes 
and in multiple carcinogenesis steps, which are clearly influenced by reactive stroma, 
we investigated the role of cation channels in the tumour-stroma crosstalk.  
Starting from this, the most up-modulated voltage-gated channel genes in CAFs, 
namely CACNA1H, CACNB1, CACNB3, SCN2A, SCN1B and KCNS3, were selected 
and their role in fibroblast activation was evaluated. Initially, we validated our gene 
expression data by assessing the expression levels of the following cation channels 
CACNA1H, CACNB1-3, SCN2A, SCAN1B, and KCNS3 in an independent panel of 
three paired CAFs and HPFs isolated from clinical samples collected at our Institute. 
Such cation channels were confirmed to be significantly up modulated in CAFs 
compared to HPFs, at both the mRNA and protein levels (Figure 4.3). Moreover, in 
agreement with our starting point, observations derived from the analysis of a public 
data set, which includes several paired prostate CAFs and HPFs (Figure 4.2), confirmed 
that the “voltage-gated cation channel activity” gene set was enriched in genes up-
regulated in CAFs.  
Once validated our gene expression results, we experimentally confirmed the 
involvement of cation channels in fibroblast activation, by performing an in vitro 
activation of fibroblasts, in which HPFs were exposed to conditioned medium (CM) of 
DU145 cells. As a result, HPFs exposed to PCa stimuli were characterised by a 
simultaneous up-modulation of fibroblast activation markers and cation channels, thus 
suggesting the involvement of ion channels in fibroblast activation process (Figure 4.4 





These observations provided the first functional evidence of a possible role of cation 
channels in prostate CAF activated phenotype, and prompted us to investigate drug-
based strategies aimed at counteracting CAF activated phenotype by targeting cation 
channels. 
Once the involvement of cation channels in fibroblasts activation was confirmed, the 
potential of specific drugs able to block the activity of the channels that we found up-
regulated was assessed in order to potentially revert CAF activated phenotype. By 
following a drug-repositioning approach, we selected amiodarone, verapamil, 
nifedipine and flecainide, which are common antiarrhythmic drugs used in the clinical 
practice to control and regulate the cardiac rhythm 
117
. Specifically, we packed-out 
amiodarone, a class II agent able to inhibit potassium (e.g. KCNS3) as well as calcium 
and sodium channels 
135
, verapamil and nifedipine, class IV agents able to counteract 
the activity of calcium channels (e.g. CACNA1H, CACNB1-3) 
136
, and flecainide, a 
class Ic drug active against sodium channels (e.g. SCN2A, SCAN1B) 
137
.  
Several studies defined CAFs as a heterogeneous cell population, characterised by the 
expression of various mesenchymal proteins. However, none of the CAF markers 
described so far is peculiar for this cell type 
138
. According to the variety of factors 
associated with CAF activated phenotype, we found that α-SMA and collagen1a1, 
which are the most widespread fibroblast activation markers, were slightly reduced in 
CAFs upon antiarrhythmics treatment, even if with different extent depending on the 
drug and the doses (Figure 4.8).  
In order to create a permissive environment for cancer cells, CAFs are characterised by 
an enhanced cell motility and an increased extracellular matrix (ECM) production and 
remodelling activities 
118





potential and ECM remodelling effectiveness were assessed. Interestingly, 
antiarrhythmics were able to reduce CAF motility (Figure 4.9) by impairing focal 
adhesion formation during CAF migration process, as assessed by a decreased FAK 
phosphorylation expression (Figure 4.10). Moreover, ECM remodelling capability of 
CAFs was affected upon the treatment (Figure 4.11), suggesting that antiarrhythmics 
could reduce CAF-induced desmoplastic reaction and potentially affect metastatic 
processes. Altogether, these changes indicated that antiarrhythmics were able to induce 
in CAFs a phenoconversation from an activated phenotype, characterised by the up-
modulation of fibroblast activation markers, migration and ECM remodelling potential, 
to a more quiescent state that resembled that of HPFs. 
Despite the elevated inter-individual heterogeneity that characterises CAF phenotype, 
the similarities between HPFs and antiarrhythmic treated-CAFs were further confirmed 
by gene expression profiling analysis. According to PCA analysis, antiarrhythmic 
treated-CAF profiles were found spatially aligned in-between HPF and CAF profiles, 
which instead were clearly sorted (Figure 4.12). Moreover, interesting communalities 
between HPFs and antiarrhythmic-treated CAFs were clarified by GSEA. Notably, , 
EMT-related gens, glycolysis, hypoxia, protein secretion pathways and TGF- β 
signalling were found to be simultaneously down-modulated in antiarrhythmic-treated 
CAFs and HPFs compared to CAFs (Figure 4.13 and 4.14). In contrast, the up-
modulation of those gene sets was found in CAFs (Figure 4.13 and 4.14). These 
findings are in line with the role of TGF-β signalling in PCa tumour microenvironment. 
As well established, TGF-β signalling activation in prostate fibroblasts is associated 
with a tumour-promoting phenotype, which relies on the secretion of tumourigenic 
factors, such as CXCL-12 
139
. In addition, CAFs in PCa tumour microenvironment are 





growth. Specifically, cancer cells are able to induce the shift of CAFs from an oxidative 
phosphorylation metabolism to aerobic glycolysis, through TGF-β signalling activation 
68,69,140
. Interestingly, in our antiarrhythmic-treated CAFs setting, the simultaneous 
down-modulation of TGF-β signalling, glycolysis, hypoxia and protein secretion 
pathways was indicative of a possible role of antiarrhythmics as suppressors of the 
metabolic boost provided by CAFs to PCa cells.  
Overall, these findings highlighted that antiarrhythmics are able to substantially shift 
CAF-activated phenotype into HPFs, mainly by inhibiting CAF motility and ECM 
remodelling capability and also suppressing CAF-metabolic reprogramming induced by 
PCa cells. 
It is well known that the progression of cancer cells into a fully malignant tumoural 
mass is actually supported by tumour-stroma interactions 
141
. In PCa, as well for many 
types of tumours, it has been reported that CAFs are engaged in cancer progression, 
mainly by inducing the EMT shift and metastatic dissemination, and as well by 
establishing a mutual metabolic reprogram of cancer cells 
83,120
. On this basis, we 
investigated the biological effects of antiarrhythmics on CAF-PCa cell interplay, by 
performing CM-based indirect co-culture. Considering the relevance of CAF-
promoting effects on cancer cell growth, the impact of antiarrhythmics on CAF-
mediated PCa cell proliferation was evaluated. Interestingly, CM of CAFs treated with 
antiarrhythmics was able to significantly reduce PCa cell growth, partially 
recapitulating tumour suppressive effects mediated by CM of HPFs on PCa cells 
(Figure 4.16). In addition, the reduction of PCa cell proliferation induced by CM of 
CAFs exposed to antiarrhythmics was associated mainly with the induction of 





proliferation by CAFs was not observed in our experimental setting. In this regard, 
controversial information has been reported regarding the ability of CAFs to promote 
cell growth of PCa cell lines. In fact, metastatic-PCa cell lines were shown to be less 
sensitive to the CAF-induced proliferative spur than non-metastatic cell lines 
79
. 
Regarding EMT modulation, the role of CAFs in promoting EMT in tumour cells has 
been instead established in many cancers, as well in the PCa setting 
120
. Consistent with 
this role, a shift from a epithelial-like to a mesenchymal-like phenotype was observed 
in DU145 cells exposed to CM from CAFs (Figure 4.18). Surprisingly, a significant 
improvement of cell organised in clusters was found in DU145 cells cultured with CM 
of antiarrhythmic-treated CAFs, as well with CM-HPFs (Figure 4.18). These changes 
were consistent with the increased amount of E-cadherin and β-catenin found in DU145 
cells cultured with CM of antiarrhythmic-treated CAFs or of HPFs. In contrast, 
decreased levels of E-cadherin and β-catenin, with concomitant up-modulation of 
vimentin and snail were detected in DU145 cells exposed to CM from untreated CAFs 
(Figure 4.17). Altogether, these findings indicate that antiarrhythmics are able not only 
to abrogate CAF-induced EMT in DU145 cells but also to revert the mesenchymal 
phenotype, as observed with HPFs. Given the relevance of migration processes in 
cancer dissemination, we also found that antiarrhythmics were able to influence CAF-
mediated PCa cell migration. Specifically, CM of CAFs treated with nifedipiine and 
flecainide – two of our most promising drugs – was able to significantly reduce DU145 
cell migratory potential (Figure 4.20). Furthermore, since MMPs are essential for cell 
migration and invasion, we investigated whether antiarrhythmics were able to 
counteract their expression/secretion by CAFs (120) . Interestingly, the levels of MMP-
2 were found to be reduced in the CM of CAFs treated with nifedipine or flecainide 





MMP-2 was produced and released in the interstitial tissues by prostate CAFs, thus 
promoting a marked remodelling of the stroma, and fostering PCa invasion and 
dissemination 
121
. Overall, these findings indicated that antiarrhythmics were able to act 
on CAF-PCa interaction, mainly by reverting the CAF-induced EMT and potentially by 
impairing PCa cell invasion 
On this promising basis, we were strongly encouraged to pursue the investigation of 
antiarrhythmics effect in the in vivo setting. Consistent with the in vitro observations, 
intratumoural injection of CM of CAFs treated with antiarrhythmics was able to 
significantly delay tumour growth (Figure 4.25 and Figure 4.26) and reduce E-cadherin 
expression of PCa xenografts (Figure 4.27).  
Overall, this study provided evidence that antiarrhythmics could act as promising 
inhibitors of CAF-PCa interplay in vitro and in vivo. Actually, CAF-mediated tumour 
promoting effects, especially with respect to the ECM remodelling capability and CAF-
induction of EMT in PCa cells, were substantially affected by antiarrhythmics 
treatment. in addition considering the impact of the tumour microenvironment in 
shaping PCa cell metabolism and vice versa, antiarrhythmic promising suppressive 
potential of CAF metabolic pathways could be further invistigated in order to abrogate 
the reciprocal metabolic interaction between PCa cells and reactive stroma. Our 
findings may open new innovative opportunities for the translation of drugs already 
used in the cardiovascular field, specifically those targeting voltage gated cation 
channels, into novel anticancer regimens, aimed at interrupting the tumour-supportive 






6.2. Identification of potential stromal biomarkers for risk assessment in AS 
patients  
AS is a conservative management approach aimed to prevent overtreatment in PCa 
patients with very low-risk and clinically insignificant disease, characterised by a 
limited metastatic potential 
142
. During AS the signs of the disease are monitored every 
3 months, trough PSA level evaluation and digital rectal examination, and a prostate 
core biopsy is scheduled every 12-24 months 
122
. However, the criteria for the correct 
identification of AS candidates are actually suboptimal and approximately 25% of the 
patients enrolled discontinue the protocol due to disease reclassification, mainly for the 
detection of GS>3+3 tumour cores at the first re-biopsy 
143
. In this regard, together with 
the commitment to avoid low-risk PCa overtreatment, the main purpose of a successful 
AS protocol is the early and correct discrimination between truly clinically insignificant 
PCa patients and carriers of occult high-risk cancer, in order to guide patients toward 
the most appropriate treatment 
144
. This frame highlights the immediate need of novel 
selection criteria for AS patients, which may reduce misclassifications. To address 
these limits, we hypothesized that the presence of a reactive stroma could be relevant 
for the early detection of significant PCa foci. This hypothesis was sustained by the 
emerging evidence highlighting the role of tumour microenvironment in PCa 
carcinogenesis. In this regard, it has been largely reported that stromal changes occur as 
an early phenomenon in PCa and correlate with the aggressiveness of the disease. For 
instance, the number of CAFs present in the reactive stroma was increased in higher-
grade disease, with respect to prostatic intraepithelial neoplasia (PIN) or low-grade PCa 
70
. Specifically, Ayala and collaborators showed that the reactive stroma volume 
correlates with biochemical recurrence in PCa patients, highlighting that patients with 







extracellular matrix (ECM) proteins, including collagen, fibronectin and tenascin, were 
found up-modulated in the PCa reactive stroma. Among these proteins, the authors 
identified desmin and α-SMA as reactive stroma hallmarks associated with recurrence 
in PCa patients 
74
. In addition, Mo and colleagues characterised a stroma-derived 
metastatic signature able to discriminate between metastatic and non-metastatic PCa 
PDX models 
145
, further confirming that the stromal component could be actually 
considered as an important source of information useful to predict patient outcome.  
In this frame, our idea was to define a peculiar reactive stroma signature associated 
with high-grade PCa foci, in order to improve AS selection criteria and potentially 
predict patient outcome. As anticipated, we performed a gene expression profiling of 
prostate derived-CAFs and normal fibroblasts (HPFs) activated in vitro with IL-6 and 
TGF-β. In this setting, we analysed and selected those genes that we found to be 
significally up-modulated in at least one of our set of activated fibroblasts. This 
criterion of selection is based on the assumption that CAFs and “in vitro activated 




Accordingly, considering the relevance of ECM deregulation in reactive stroma, we 
found a panel of five ECM proteins up-modulated in our set of activated fibroblasts 
(Figure 5.2). Specifically, we identified postn, col11a1, col10a1, sparc and comp, 
which encode for ECM proteins found to be associated with reactive stroma in several 
tumours 
146
. Initially, we focused on POSTN, which is the most up-modulated ECM 
gene in CAFs and in vitro activated fibroblasts (Figure 5.2). POSTN gene encodes for 
periostin, a glycoprotein protein involved in the ECM deposition that has been reported 






. In 2018, Cattrini and collaborators established the relevance of periostin in 
PCa stroma. In this study, they showed the association of periostin expression levels 
and patient outcome 
150
. Consistent with the emerging role of periostin in the PCa 
tumour we observed that high expression levels of periostin mRNA were significantly 
correlated with a higher probability to experience biochemical recurrence (BCR), 
which is the rise of PSA blood levels upon radical treatment (e.g radical prostatectomy 
or radiotherapy), in PCa samples from public database (Figure 5.3).  
These observations prompted us to investigate the potential of periostin as a risk-
assessment biomarker in AS setting. Specifically, our hypothesis was to correlate 
stromal periostin expression levels with the presence of undetected high-grade PCa 
foci, in order to reduce the disease misclassification during PCa diagnosis. Consistent 
with literature data, results derived from our explorative cohort of 116 prostatectomy 
samples, collected in our institute, indicated that periostin expression was significantly 
increased in the tumoural stroma component surrounding Gleason score (GS) > 7 PCa 
foci, with respect to GS ≤ 6 (Figure 5.5). More interestingly, high periostin expression 
levels were found significantly associated with a specific subgroup of GS 7 tumours 
(Figure 5.6). The GS 7 tumours are mainly classified by the detection of the Gleason 
patterns 3 and 4 (3+4 or 4+3) within the tumour foci. Patients with GS 7 tumours were 
characterised by a wide spectrum of clinical outcomes, ranging from a more favourable 
outcome to the worst one 
151
. This scenario highlighted the urgent needed of novel 
outcome predictors for these intermediate PCa tumours. Recently, has been shown that 
a subgroup of GS 7 tumours are characterised by cribriform growth in the Gleason 
pattern 4. Unfortunately, these patients display a worse prognosis with respect to GS 7 
tumours without cribriform morphology. This finding suggests that cribriform 





to the relevant impact on patient outcome of this subgroup of tumours 
127
. The 
significant association of periostin staining and cribriform morphology in pattern 4 
(Figure 5.5) further supports our idea that the presence of a peculiar reactive stroma 
could be relevant for the early identification of specific subset of aggressive PCa foci. 
Finally, given the ability of a reactive stroma to support cancer progression, the 
prognostic relevance of periosin staining was evaluated. Despite the expectations, the 
univariate models indicated that periostin displayed a moderate capability to predict 
biochemical failure in our cohort (Figure 5.7).  
As mentioned above, our initial hypothesis was to detect the presence of specific 
reactive stroma in core biopsies obtained at the diagnosis of AS patients in order to 
identify the presence of a suspicion aggressive disease and avoid the inclusion in AS 
apparently indolent PCa patients. Unfortunately, several technical issues and legal 
aspects, related to the concrete possibility of destroy these precious samples prompted 
us to investigate alternate strategies for achieving our aim.  
Given the well-documented possibility to detect circulating tumour cells (CTCs) and as 
well tumour-derived molecules, including mRNAs and exosomes, in the blood of 
cancer patients, we sought to test the relevance of our ECM signature as circulating 
biomarker for AS patients risk assessment 
152
. Currently, no considerable evidence has 
been collected regarding the potential of stromal circulating signatures in the PCa 
context. However, our hypothesis was supported by the evidence that tumour-derived 
molecules, as well CTCs, were found in the blood of PCa patients and their levels 
correlate with disease classification and patient outcome. Specifically, it has been 
showed that CTCs obtained from PCa patients harbour peculiar alterations such as 
TMPRSS2-ERG fusions, PTEN deletions and AR copy number changes, typically 
associated with PCa 
153





number of CTCs correlates with poor overall survival in castration-resistant PCa 
patients 
154
. Concerning the potential of miRNAs as novel PCa biomarkers, altered 
miRNA expression profiles were found in tumoural tissues, as well as in serum and 
plasma of PCa patients compared to normal tissues and healthy donors 
155
. Specifically, 
a panel of 15 miRNAs (miRNA-16, miRNA-31, miRNA-125b, miRNA-145, miRNA-
149, miRNA-181b, miRNA-184, miRNA-205, miRNA-221, miRNA-222, miRNA-96, 
miRNA-182, miRNA-182*, miRNA-183, miRNA-375) displayed a considerable 
capability to discriminate normal prostate from PCa tissue with accuracy up to 84% 
156
. 
Moreover, Mitchell and colleagues reported that serum levels of miRNA-141 were able 
to distinguish PCa patients from healthy donors 
157
. Due to their obvious potential and 
stability in the biologic fluids, miRNAs have emerged as promising diagnostic and 
prognostic biomarkers able to define tumour staging and treatment responses in PCa 
patients 
158
. Finally, in the last decade, exosomes have emerged as novel circulating 
disease biomarkers in PCa setting. Interestingly, tumour derived-exosomes could carry 
specific miRNAs and proteins associate with the tumour. In this regard, an increased 
amount of prostate-derived vesicles was found to be associated with aggressive disease 
in PCa patients 
158
. In addition, miRNA-profiling analysis of serum-derived exosomes 
revealed an association of miR-141 and miR-375 with metastatic PCa 
159,160
 Moreover, 
higher levels of Survivin were found in plasma-derived exosomes isolated form PCa 
patients compared to donors, suggesting that tumour-derived molecules, including 
proteins, could be uses as circulating biomarkers for early detection of PCa 
161
. 
Notably, the cells of origin of such circulating molecules, which reflect the tumour 
stage and patient outcome, are unknown and it cannot be excluded that circulating 
molecules could be released in the biologic fluid by reactive stroma surrounding the 





In this study, we assessed plasma levels of periostin, col11a1, col10a, comp and sparc 
in order to correlate their expression with AS patients’ outcome. The feasibility of our 
hypothesis was initially supported by the evidence that periostin, col11a1, coll10a1, 
sparc and comp were found extensively released in the CM of CAFs (Figure 5.8) and in 
the plasma of PCa patents (Figure 5.9), especially in those who harbour clinically 
significant disease.  
On this basis, we evaluated the plasma levels of periostin, coll11a1, col101, comp and 
sparc in an explorative cohort of AS patients by using ELISA assay. No significant 
difference was found between plasma levels of ECM proteins at the baseline in 
upgrading vs indolent patients (Figure 5.10). Interestingly, only sparc displayed a 
limited capability to discriminate upgrading patients from indolent ones (Figure 5.10). 
However, the combination of sparc and periostin in logistic models revealed a moderate 
potential of our candidates to predict upgrading event at the baseline (Figure 5.11 and 
5.12). Unfortunately, this moderate predictive potential obtained by combining sparc 
and priostin was not confirmed in an additional cohort of AS patients (Figure 5.13 and 
5.14).  
Overall, considering the several limitations concerning the study of this peculiar 
subgroup of PCa patients, our preliminary findings could provide the basis for develop 
novel strategies for the investigation of circulating molecules derived from the reactive 
stroma in AS setting. Indeed, patients eligible for AS are characterized by limited 
tumour burden and a very low-risk disease. This unique setting needs novel biomarkers 
characterized by a high specific potential to discriminate at the baseline between 






However, the relevance of circulating periostin was confirmed in the plasma of patient 
with clinically significant PCa subjected to RT. Specifically, periostin circulating levels 
were found increased up to 20 compared to the levels observed in AS patients, 
suggesting that the use of more sensible detection methods could be relevant in the 
study of circulating biomarkers for cohort patients with apparently homogeneous 
characteristics, as are AS patients. In this regard, the concrete possibility to detect 
tumour related biomarkers in the urine sample of AS patients could overpass such 
limited conditions. It has been reported that urine samples from PCa patients were 
enriched with tumour components, as well as reactive stroma.  
In this complex scenario, additional efforts are required to identify robust novel 
circulating biomarkers that, in combination with the currently used clinico-pathological 
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